Official Protocol Title:
NCT number:
Document Date:
A Multiple Ascending Dose Clinical Study to 
Evaluate the Safety, Tolerability, PK and the 
Effect of MK-8189 on QTc in Participants with 
Schizophrenia
 18-Nov-2022[STUDY_ID_REMOVED]
PRODUCT: MK-8189  1
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC , RAHWAY, NJ, [LOCATION_003] (MSD )
Protocol Title: A Multiple Ascending Dose Clinical Study to Evaluate the Safety, 
Tolerability, PK and the Effect of MK -8189 on QTc in Participants with Schizophrenia
Protocol Number: 014-05
Compound Number: MK-8189
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_952521], NJ [ZIP_CODE] [LOCATION_003]
Regulatory Agency Identifying Number(s):
IND 118,986
Approval Date: [ADDRESS_952522]: MK-8189  2
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08D4MT
PRODUCT: MK-8189  3
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952523] of Panel C without review of Panel A -1 PK as it has been determined that 
even if PK is not predicted to achieve 2 -fold the high clinical exposure scenario ,lower 
exposures may support an integrated (non-clinical and clinical) concentration -QTc 
analysis that may negate the need for a TQT study (ICH E14 & S7B Q&A August 2022).
In addition, as evaluation of an MK -[ADDRESS_952524]: MK-8189  4
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 05
Overall Rationale for the Amendments:
Conducting Panel C may support an integrated (non-clinical and clinical) concentration -QTc analysis negating the need for a TQT 
study per ICH E14 & S7B Q&A August 2022. It has been determined that even if PK is not predicted to achieve 2 -fold t he high 
clinical exposure scenario, a concentration -QTc analysis at lower exposures may still negate the need for a TQT study. Additionally, 
since lower doses of MK -8189 may also support an integrated concentration -QTc analysis, language has been removed t hat did not 
allow for Panel C if the dose regimen administered in Panel A -1 was not tolerated. If the Panel A -1 dose regimen is not tolerated, a 
lower dose in Panel C may be evaluated per Section 8.10.6 (Study Design/Dosing/Procedures Modifications Permitt ed withing 
Protocol Parameters) of the protocol. To note, in Panel A of the current protocol, preliminary blinded data indicate doses up to and 
including MK -8189 60 mg are generally well tolerated (Section 4.3.1). 
Summary of Changes Table:
Section # and Name [CONTACT_11029]  
4.[ADDRESS_952525]: MK-8189  5
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Section # and Name [CONTACT_11029]  
4.2 Scientific Rationale for 
Study DesignAdded language that a concentration QTc 
analysis at lower exposures may negate 
need for TQT study if supported by [CONTACT_105] -
clinical data. Added reference to ICH E14
&S7B Q&A regulatory guidance .Confirmation of exposures 2 -fold the high clinical 
exposure scenario in Panel A -1 is not critical to dose 
regimen for Panel C .
4.3.1 Starting Dose for this 
StudyUpdated language to say that p reliminary 
blinded data from Panel A demonstrated 
good tolerability of MK -8189 48 
mg/placebo administered on Day 1 and 
MK-8189 80 60 mg/placebo administered 
on Day 2, (i nstead of previous 80 
mg/placebo on Day 2).Minor edit to update erroneous text .
4.3.2 Maximum 
Dose/Exposure for This 
StudyRemoved language requiring the review of 
PK data from Panel A -1 prior to initiation 
of Panel C. Added language that MK -8189 
exposures at 80 mg or lower may be 
sufficient to support an integrated waiver 
assessment. Added reference to ICH 
guideline E14 & S7B Q&A  August 2022.Confirmation of exposure s 2-fold the high clinical 
exposure scenario is no longer critical for conduct of 
Panel C.
4.3.[ADDRESS_952526]: MK-8189  6
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 14
1.1 Synopsis ................................................................................................................. 14
1.2 Schema .................................................................................................................. 17
1.3 Schedule of Activities........................................................................................... 18
2 INTRODUCTION .......................................................................................................... 30
2.1 Study Rationale ....................................................................................................30
2.2 Background .......................................................................................................... 30
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 30
2.2.2 Preclinical and Clinical Studies ...................................................................31
2.2.3 Ongoing Clinical Studies ............................................................................. 32
[IP_ADDRESS] Protocol 011 ....................................................................................... 32
[IP_ADDRESS] Protocol 012 ....................................................................................... 35
[IP_ADDRESS] Protocol 015 ....................................................................................... 35
[IP_ADDRESS] Protocol 013 ....................................................................................... 36
[IP_ADDRESS] Protocol 016 ....................................................................................... 36
[IP_ADDRESS] Protocol 008 ....................................................................................... 37
2.2.4 Information on Other Study -related Therapy .............................................. 38
2.3 Benefit/Risk Assessment ...................................................................................... 38
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 38
4 STUDY DESIGN ............................................................................................................ 39
4.1 Overall Design ......................................................................................................39
4.2 Scientific Rationale for Study Design ................................................................ .41
4.2.1 Rationale for Endpoints ............................................................................... 42
[IP_ADDRESS] Efficacy Endpoints ............................................................................. 42
[IP_ADDRESS] Safety Endpoints ................................................................................ 42
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 43
[IP_ADDRESS] Pharmacodynamic Endpoints............................................................. 43
[IP_ADDRESS] Planned Exploratory Biomarker Research .........................................43
[IP_ADDRESS].1 Planned Genetic Analysis ........................................................ 43
[IP_ADDRESS] Future Biomedical Research .............................................................. 44
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. [ADDRESS_952527]: MK-8189  7
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
4.3.1 Starting Dose for This Study ........................................................................ 45
4.3.2 Maximum Dose/Exposure for This Study ................................................... 45
4.3.3 Rationale for Dose Interval and Study Design ............................................ 49
4.4 Beginning and End-of-Study Definition ............................................................ 49
4.4.1 Clinical Criteria for Early Study Termination ............................................. 50
5 STUDY POPULATION ................................................................................................ 50
5.1 Inclusion Criteria ................................................................................................ .50
5.2 Exclusion Criteria ................................................................................................ 53
5.3 Lifestyle Considerations ...................................................................................... 56
5.3.1 Meals and Dietary Restrictions ....................................................................56
[IP_ADDRESS] Diet Restrictions................................................................................. 56
[IP_ADDRESS] Fruit Juice Restrictions ......................................................................57
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 57
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 57
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 57
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 57
5.3.3 Activity Restrictions .................................................................................... 57
5.4 Screen Failures .....................................................................................................58
5.5 Participant Replacement Strategy ......................................................................58
6 STUDY INTERVENTION ............................................................................................ 58
6.1 Study Intervention(s) Administered ...................................................................58
6.2 Preparation/Handling/Storage/Accountability ................................................. 60
6.2.1 Dose Preparation .......................................................................................... 60
6.2.2 Handling, Storage, and Accountability ........................................................ 60
6.3 Measures to Minimize Bias: Randomization and Bl inding .............................. 61
6.3.1 Intervention Assignment.............................................................................. 61
6.3.2 Stratification ................................................................................................ .62
6.3.3 Blinding ........................................................................................................62
6.4 Study Intervention Compliance .......................................................................... 62
6.5 Concomitant Therapy .......................................................................................... 62
6.5.1 Rescue Medications and Supportive Care ................................................... 63
6.6 Dose Modification (Escalation/Titration/Other) ............................................... [ADDRESS_952528]: MK-8189  8
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952529] to Follow -up................................................................................................ .66
8 STUDY ASSESSM ENTS AND PROCEDURES ........................................................ 66
8.1 Administrative and General Procedures ........................................................... 67
8.1.1 Informed Consent ......................................................................................... 67
[IP_ADDRESS] General Informed Consent ................................................................ .67
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 68
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_952530] .....................................................................68
8.1.4 Medical History ........................................................................................... 68
8.1.5 Prior and Concomitant Medications Review ............................................... 69
[IP_ADDRESS] Prior Medications ............................................................................... 69
8.1.6 Assignment of Screening Number ............................................................... 69
8.1.7 Assignment of Treatment/Randomization Number .....................................69
8.1.8 Study Intervention Administration .............................................................. 70
[IP_ADDRESS] Timing of Dose Administration ......................................................... 70
8.1.9 Discontinuation and Withdrawal ................................................................ .70
[IP_ADDRESS] Withdrawal From Future Biomedical R esearch ................................ 70
8.1.10 Participant Blinding/Unblinding ..................................................................71
8.1.11 Domiciling ...................................................................................................71
8.1.12 Calibration of Equipment ............................................................................. 71
8.2 Efficacy Assessments ........................................................................................... 72
8.3 Safety Assessments ............................................................................................... 72
8.3.1 Physical Examinations ................................................................................. 72
8.3.2 Vital Signs ....................................................................................................72
[IP_ADDRESS] Resting Vital Signs ............................................................................ 73
[IP_ADDRESS] Orthostatic Vital Signs .......................................................................73
8.3.3 Electrocardiograms ...................................................................................... 73
8.3.4 Clinical Safety Laboratory Assessments ..................................................... 75
8.3.5 Pregnancy Testing ........................................................................................ 75
8.3.6 Suicidal Ideation and Behavior Mo nitoring ................................................. 76
[IP_ADDRESS] Clinical Assessments for Suicidal Ideation and Behavior 
Monitoring ......................................................................................... 76
[IP_ADDRESS] Monitoring for Extrapyramidal Symptoms ........................................[ADDRESS_952531]: MK-8189  9
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 77
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......79
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...79
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 79
8.4.5 Pregnancy and Exposure During Breastfeeding .......................................... 80
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_952532] ............................................................................ 80
8.4.8 Medical Device and Drug -device Combination Products -
PQCs/Malfunctions ...................................................................................... [ADDRESS_952533] ion............................................... 82
8.10 Visit Requirements ............................................................................................... 82
8.10.1 Screening ......................................................................................................82
8.10.2 Treatment Period .......................................................................................... 83
8.10.3 Participants Discontinued From S tudy Intervention but Continuing to be 
Monitored in the Study ................................................................................ 83
8.10.4 Poststudy ......................................................................................................83
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedure .......83
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 85
9 STATISTICAL ANALYSIS PLAN ............................................................................. 86
9.1 Statistical Analysis Plan Summary .....................................................................86
9.2 Responsibility for Analyses ................................................................................. 86
9.3 Hypotheses/Estimation ........................................................................................ [ADDRESS_952534]: MK-8189  10
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........ 90
10.1.1 Code of Conduc t for Clinical Trials ............................................................. 90
10.1.2 Financial Disclosure ..................................................................................... 92
10.1.3 Data Protection ............................................................................................. 93
[IP_ADDRESS] Confidentiality of Data ......................................................................93
[IP_ADDRESS] Conf identiality of Participant Records ............................................... 93
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ 93
10.1.4 Publication Policy ........................................................................................ 94
10.1.5 Compliance with Study Registration and Results Posting Requirements ...94
10.1.6 Compliance w ith Law, Audit, and Debarment ............................................ 94
10.1.7 Data Quality Assurance ............................................................................... 95
10.1.8 Source Documents ....................................................................................... 96
10.1.9 Study and Site Closure ................................................................................. 96
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 97
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 99
10.3.1 Definitions of Medication Error, Misuse, and Abuse ..................................99
10.3.2 Definition of AE .......................................................................................... 99
10.3.3 Definition of SAE ...................................................................................... 100
10.3.4 Additional Events Reported .......................................................................101
10.3.5 Recording AE and SAE ............................................................................. 102
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events t o the 
Sponsor ......................................................................................................105
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up............................................................................................................ 107
10.5 Appendix 5: Contraceptive Guidance .............................................................. 108
10.5.1 Definitions..................................................................................................108
10.5.2 Contraception Requirements ......................................................................109
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 110
10.7 Appendix 7: Country -specific Requirements .................................................. 115
10.8 Appendix 8: Blood Volume Table ....................................................................116
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteria .................. 117
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values ...119
10.11 Appendix 11: Neurological Exam .....................................................................120
10.11.1 General (Full) Neurological Exam ............................................................. 120
10.11.2 Targeted Neurological Exam .....................................................................125
10.12 Appendix 12: Abbreviations ............................................................................. [ADDRESS_952535]: MK-8189  11
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952536]: MK-8189  12
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952537] e Allocation Schedule ............................. 61
Table 4 Panel C Schizophrenic Sample Allocation Schedule ................................ .61
Table 5 Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events ................................................................ .78
Table 6 Pharmacokinetic (Blood) Collection Windows for samples not time -
matched to Holter ECG assessments ......................................................... [ADDRESS_952538]: MK-8189  13
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952539] OF FIGURES
Figure 1 Study Schema ............................................................................................. 17
Figure 2 Study Design – Decision Tree ...................................................................40
Figure 3 MK-8189 Dose -Enzyme Occupancy ......................................................... 46
Figure 4 Predicted Mean ΔΔQTcF Versus the Observed Geometric Mean Cmax 
for Each Dose Level Along With 90% Confidence Band ......................... [ADDRESS_952540]: MK-8189  14
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Multiple Ascending Dose Clinical Study to Evaluate the Safety, 
Tolerability, PK and the Effect of MK -8189 on QTc in Participants with Schizophrenia
Short Title: MK- 8189 Multiple Ascending Dose Clinical Study in Participants with 
Schizophrenia
Acronym: MAD
Hypotheses, Objectives ,and Endpoints :
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
The following objectives will be eval uated in male and female participants with 
schizophrenia:
Objectives Endpoints
Primary
•To evaluate the safety and tolerability of 
multiple ascending doses of MK -8189 in 
participants with schizophrenia•Adverse events , discontinuation of 
study intervention due to adverse 
events
Overall Desig n:
Study Phase Phase [ADDRESS_952541]: MK-8189  15
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952542] participant 
(or their legally acceptable representative) provides 
documented informed consent until the last participant’s 
last study- related contact .
Number of Participant s:
Up to 12 participants with schizophrenia will be allocated/randomized for each of Panels A 
andA-1,such that approximately 8 participants are evaluable and complete the study in each 
of these panels. Up to 30 participants with schizophrenia will be allocated/rand omized for 
Panel C such that up to 20 partic ipants are evaluable andcomplete the study in each of these 
panels as described in Section 9.9.
Intervention Groups and Du ration :
Intervention 
Group sInter -
vention 
Group 
Name [CONTACT_88729]/ 
Treatment 
Period/ 
Vaccination 
Regimen Use
Active
Panel AMK-[ADDRESS_952543]: MK-8189  16
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Total 
Number of 
Intervention 
Groups/
Arms2 intervention groups
Duration of 
ParticipationPanel A and A -1:Each participant will participate in the study for 
approximately [ADDRESS_952544]. After a screening, phase of 6
weeks, each participant will receive assigned intervention for 
approximately 2 days. After the end -of-treatment each participant will be 
followed for 2 weeks.
Panel C : Each participant will participate in the study for approximately [ADDRESS_952545]. After a screening, phase of 6weeks, each 
participant will receive assigned intervention for approximately 3days. 
After the end -of-treatmen t each participant will be followed for 2 weeks.
Study Governance Committees:
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations is in Appendix 2.
08D4MT
PRODUCT: MK-8189  17
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952546]: MK-8189  18
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
1.3 Schedule of Activities
Panel A
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952547]-
studyScreening should occur within 6 weeks prior 
to Day 1
Administrative Procedures
Informed Consent X Sec. 8.1.1
Informed Consent for FBR X Sec. [IP_ADDRESS]
Participant ID Card X Sec. 8.1.3
Inclusion/Exclusion Criteria X XSec. 5.1, Sec. 5.2 Specific criteria may be 
reviewed before randomization
Medical History (includes 
psychiatric
history and substance usage)XSubstances: Drugs, alcohol, tobacco, and 
caffeine
Prior/Concomitant Medication 
ReviewX X X X X X X X X X X Sec. 8.1.[ADDRESS_952548] 3 half -
lives (whichever is longer) prior to Day -1. 
For long half -life drugs washout may begin 
on outpatient basis (Sec. 4.1)
Assignment of Treatment Number X Sec. 8.1.[ADDRESS_952549]: MK-8189  19
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952550]-
studyScreening should occur within 6 weeks prior 
to Day 1
Full Neurological Examination X X XDay -1: within [ADDRESS_952551] dose. Upon 
discharge on Day 5.
Sec. 8.3.7 and Appendix 11
Targeted Neurological Examination X X X X XDay 1 -5: up to 3 hours pre -dose or 
equivalent. 
Poststudy visit.
Sec. 8.3.7 and Appendix 11
Vital Signs (HR, BP) cX X X X X X X X Sec. 8.3.2
Vital Signs (respi[INVESTIGATOR_270014], temperature)X X XdXdXdX X XAnytime during screening, Day -1 and 
poststudy visit. 
Predose on Day 1 -2 and at 9 hours postdose 
(or equivalent) on Day 1 -4. Upon discharge 
on Day 5.  Sec. 8.3.2.
12-lead ECG eX X X X X X X X Sec. 8.3.3
Serum
(hCG; WOCBP only)X X
Urine or Serum Pregnancy Test 
(WOCBP only)XUrine test will be collected. Serum test will 
be collected in the event that Urine test is 
positive or cannot be confirmed.
Serum FSH -(WONCBP) X
HIV, hepatitis B and C screen (per 
site SOP)X
UDS/BDS (per site SOP) X XScreening UDS/BDS is mandatory, any 
additional UDS/BDS are conducted per site 
SOP. UDS prior to randomization will be 
done on the day of admission.
Laboratory Safety Tests: 
(Hematology, Urinalysis, 
Chemistry)X X X X XCollected at predose (or equivalent) after ~[ADDRESS_952552]
AE/SAE review X X X X X X X X X X X
08D4MT
PRODUCT: MK-8189  20
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952553]-
studyScreening should occur within 6 weeks prior 
to Day 1
Brief Psychiatric Rating Scale 
(BPRS)X X X Xup to 3 hours pre- dose or equivalent 
timepoint Sec. 8.3.7  
C-SSRS Baseline Xup to 3 hours pre- dose equivalent timepoint 
Sec. [IP_ADDRESS] 
C-SSRS Since Last Assessment X X X Xup to 3 hours pre- dose or equivalent Sec. 
[IP_ADDRESS] 
Barnes Akathisia Rating
Scale (BARS)f X X X X XUp to 3 hours pre- dose on dosing days. Any 
time on non -dosing days Sec. [IP_ADDRESS]
Abnormal Involuntary
Movement Scale (AIMS)f X X X X XUp to 3 hours pre -dose on dosing days. Any 
time on non -dosing days Sec. [IP_ADDRESS]
Simpson Angus Scale
(SAS)f X X X X XUp to 3 hours pre- dose on dosing days. Any 
time on non -dosing days Sec. [IP_ADDRESS]
Pharmacokinetics
Blood for Plasma MK -[ADDRESS_952554]: MK-8189  21
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952555]-
studyScreening should occur within 6 weeks prior 
to Day 1
ADA=antidrug antibody; AE=adverse event; BDS=blood drug screen; C-SSRS=Columbia-Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; FBR=future biomedical research; FSH=follicle stimulating hormone; hCG= human chorionic gonadotropin ; ID=identification; SAE=serious adverse 
event; SOP=standard operating procedure; UDS= urine drug screen ; VS=vital signs; WOCBP=women of childbearing potential; WONCBP=women of nonchildbearing 
potentia l.
a.Meals should be given at approximately the same time starting on Day -1(Day -6 if washing off antipsychotic therapy) time-matched to postdose meals ,through [ADDRESS_952556] dose including; b reakfast at ~1 hour postdose, lunch at ~4 hours postdose, snack at ~8 hours postdose and dinner at ~12 hours postd ose.All subsequent meals will 
be unrestricted in timing. All meals will follow the completion of all specified procedures at that timepoint
b.Participants will be confined minimally from Day -1until Day 5procedures are complete. If participant is washing off antipsychotic therapy domiciling will begin on 
Day -6.
c.HR and BP, Day -1: Triplicate measurements time -matched to 9hours post dose equivalent measurements 
• Single HR and BP measurements will be obtained at all postdose timepoints on the following days :
• Days 1 -2: at 9hours post -dose
• Days 3-4: 9post-dose equivalent
• Days 5: Upon discharge from the clinic
d.Respi[INVESTIGATOR_170428]
e.12-lead safety ECG measurements. On the following days, specific timepoints are noted:
• Day -1: Tripli cate measurements, Time -matched to 9hours post dose equivalent measurements
• Day 1 -2: at 9hours post -dose
• Day 3-4: at 9hours post -dose equivalent
• Days 5: Upon discharge from the clinic
f.Additional BARS, AIMS and SAS assessments should be conducte d ifpossible when there are observed or reported complaints of dystonia and/or akathisia
g.MK-8189 plasma PK sample collection:
• Day 1: predose, 2 ,6, 8, 10, 12, 14, 16 hours postdose
• Day 2: predose, 2, 6, 8, 10, 12, 14, 16, 24, 48, [ADDRESS_952557] -dose
• Leftover main study plasma will be stored for future biomedical research
All Panels/Periods
08D4MT
PRODUCT: MK-8189  22
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A-1
Study Period: Screening Washout Intervention Post-study Notes
Scheduled Day Screening -[ADDRESS_952558]-studyScreening should occur within 6 
weeks prior to Day 1
Administrative Procedures
Informed Consent X Sec. 8.1.1
Informed Consent for FBR X Sec. [IP_ADDRESS]
Participant ID Card X Sec. 8.1.3
Inclusion/Exclusion Criteria X XSec. 5.1, Sec. 5.2 Specific criteria 
may be reviewed before 
randomization
Medical History (includes psychiatric
history and substance usage)XSubstances: Drugs, alcohol, tobacco, 
and caffeine
Prior/Concomitant Medication Review X X X X X X X X X X X Sec. 8.1.[ADDRESS_952559] 3 half -lives 
(whichever is longer) prior to Day -1. 
For long half -life drugs washout may 
begin on outpatient basis (Sec. 4.1)
Assignment of Treatment Number X Sec. 8.1.[ADDRESS_952560] MealsaX X X X X X Sec. 5.3.1
DomicilingbX ------- ------------------ ------------------ X
Safety Procedures
Full physical examination X X X Sec. 8.3.1
Height X
Weight X X X X BMI to be taken only at Screening
Directed Physical Examination X X Sec. 8.3.1
Full Neurological Examination X X XDay -1: within [ADDRESS_952561]: MK-8189  23
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A-1
Study Period: Screening Washout Intervention Post-study Notes
Scheduled Day Screening -[ADDRESS_952562]-studyScreening should occur within 6 
weeks prior to Day 1
Targeted Neurological Examination X X X X XDay 1 -5: up to 3 hours pre -dose or 
equivalent. 
Poststudy visit.
Sec. 8.3.7 and Appendix 11
Vital Signs (HR, BP) cX X X X X X X X Sec. 8.3.2
Orthostatic VS (HR, BP) cX X X X X X X X Sec. [IP_ADDRESS]
Vital Signs (respi[INVESTIGATOR_270014], temperature)X X XdXdXdX X XAnytime during screening, Day -1 
and poststudy visit. 
Predose on Day 1 -2 and at 9 hours 
postdose (or equivalent) on Day 1 -4. 
Upon discharge on Day 5.  Sec. 
8.3.2.
12-lead ECG eX X X X X X X X Sec. 8.3.3
Serum
(hCG; WOCBP only)X X
Urine or Serum Pregnancy Test 
(WOCBP only)XUrine test will be collected. Serum 
test will be collected in the event that 
Urine test is positive or cannot be 
confirmed.
Serum FSH -(WONCBP) X
HIV, hepatitis B and C screen (per site 
SOP)X
UDS/BDS (per site SOP) X XScreening UDS/BDS is mandatory, 
any additional UDS/BDS are 
conducted per site SOP. UDS prior to 
randomization will be done on the 
day of admission.
Laboratory Safety Tests: (Hematology, 
Urinalysis, Chemistry)X X X X XCollected at predose (or equivalent) 
after ~[ADDRESS_952563]
AE/SAE review X X X X X X X X X X X
Brief Psychiatric Rating Scale (BPRS) X X X Xup to [ADDRESS_952564]: MK-8189  24
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A-1
Study Period: Screening Washout Intervention Post-study Notes
Scheduled Day Screening -[ADDRESS_952565]-studyScreening should occur within 6 
weeks prior to Day 1
C-SSRS Baseline Xup to 3 hours pre- dose equivalent 
timepoint Sec. [IP_ADDRESS] 
C-SSRS Since Last Assessment X X X Xup to 3 hours pre- dose or equivalent 
Sec. [IP_ADDRESS] 
Barnes Akathisia Rating
Scale (BARS)f X X X X XUp to 3 hours pre- dose on dosing 
days. Any time on non -dosing days 
Sec.[IP_ADDRESS]
Abnormal Involuntary
Movement Scale (AIMS)f X X X X XUp to 3 hours pre -dose on dosing 
days. Any time on non -dosing days 
Sec.[IP_ADDRESS]
Simpson Angus Scale
(SAS)f X X X X XUp to 3 hours pre- dose on dosing 
days. Any time on non -dosing days 
Sec.[IP_ADDRESS]
Pharmacokinetics
Blood for Plasma MK -[ADDRESS_952566]: MK-8189  25
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel A-1
Study Period: Screening Washout Intervention Post-study Notes
Scheduled Day Screening -[ADDRESS_952567]-studyScreening should occur within 6 
weeks prior to Day 1
ADA=antidrug antibody; AE=adverse event; BDS=blood drug screen; C-SSRS=Columbia-Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; FBR=future biomedical research; FSH=follicle stimulating hormone; hCG= human chorionic gonadotropin ; ID=identification; SAE=serious adver se 
event; SOP=standard operating procedure; UDS= urine drug screen ; VS=vital signs; WOCBP=women of childbearing potential; WONCBP=women of nonchildbearing 
potentia l.
a.Meals should be given at approximately the same time starting on Day -1(Day -6 if washi ng off antipsychotic therapy) time-matched to postdose meals ,through [ADDRESS_952568] dose including; b reakfast at ~1 hour postdose, lunch at ~4 hours postdose, snack at ~8 hours postdose and dinner at ~12 hours postdose. All subsequent meals will 
be unrestricted in timing. All meals will follow the completion of all specified procedures at that timepoint
b.Participants will be confined minimally from Day -1until Day 5procedures are complete. If participant is washing off antipsychotic therapy domic iling will begin on 
Day -6.
c.HR and BP, Day -1: Triplicate measurements in the supi[INVESTIGATOR_2547], time-matched to 9hours post dose equivalent measurements . A single orthostatic assessment will be 
conducted following the last supi[INVESTIGATOR_701708].
• Single supi[INVESTIGATOR_701709] . On the following days , specific 
timepoints are noted
• Days 1 -2: at 9hours post -dose
• Days 3-4: 9post-dose equivalent
• Days 5: Upon discharge from the clinic
d.Respi[INVESTIGATOR_170428]
e.12-lead safety ECG measurements. On the following days, specific timepoints are noted:
• Day -1: Triplicate measurements, Time -matched to 9hours post dose equivalen t measurements
• Day 1 -2: at 9hours post -dose
• Day 3-4: at 9hours post -dose equivalent
• Days 5: Upon discharge from the clinic
f.Additional BARS, AIMS and SAS assessments should be conducted ifpossible when there are observed or reported complaints of dystonia and/or akathisia
g.MK-8189 plasma PK sample collection:
• Day 1: predose, 2 ,6, 8, 10, 12, 14, 16 hours postdose
• Day 2: predose, 2, 6, 8, 10, 12, 14, 16, 24, 48, [ADDRESS_952569] -dose
• Leftover main study plasma will be stored for future biomedical research
All Panels/Periods
08D4MT
PRODUCT: MK-8189  26
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel C
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952570]-
studyScreening should occur within 6 weeks prior 
to Day 1
Administrative Procedures
Informed Consent X Sec. 8.1.1
Informed Consent for FBR X Sec. [IP_ADDRESS]
Participant ID Card X Sec. 8.1.3
Inclusion/Exclusion Criteria X XSec. 5.1, Sec. 5.2 Specific criteria may be 
reviewed before randomization
Medical History (includes 
psychiatric
history and substance usage)XSubstances: Drugs, alcohol, tobacco, and 
caffeine
Prior/Concomitant Medication 
ReviewX X X X X X X X X X X X Sec. 8.1.[ADDRESS_952571] 3 half -
lives (whichever is longer) prior to Day -1. 
For long half -life drugs washout may begin 
on outpatient basis (Sec. 4.1)
Assignment of Treatment Number X Sec. 8.1.[ADDRESS_952572] MealsaX X X X X X X X Sec. 5.3.1
DomicilingbX ------------- ------- ------------------------------ X
Safety Procedures
Full physical examination X X X Sec. 8.3.1
Height X
Weight X X X X BMI to be taken only at Screening
Directed Physical Examination X X Sec. 8.3.1
Full Neurological Examination X X XDay -1: within [ADDRESS_952573]: MK-8189  27
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel C
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952574]-
studyScreening should occur within 6 weeks prior 
to Day 1
Targeted Neurological 
ExaminationX X X X X XDay 1 -5: up to 3 hours pre -dose or 
equivalent. 
Poststudy visit.
Sec. 8.3.7 and Appendix 11
Vital Signs (HR, BP) cX X X X X X XX X Sec. 8.3.2
Orthostatic VS (H R, BP )cX X X X X X XX X Sec. 8.3.2 .2
Vital Signs (respi[INVESTIGATOR_270014], temperature)X X XhXhXhX X X XSec. 8.3.2, anytime during screening, Day -1, 
and poststudy visit. 
Predose on Days 1 -3, and at 9 hours postdose 
(or equivalent) on Day 1-5. Upon discharge 
on Day 6 .
24-hour Holter ECG &
Extraction d X X X X X X X X
12-lead ECG eX X X X X X XX X Sec. 8.3.3
Serum (hCG; WOCBP only) X X
Urine or Serum Pregnancy Test 
(WOCBP only)XUrine test will be collected. Serum test will 
be collected in the event that Urine test is 
positive or cannot be confirmed.
Serum FSH -(WO NCBP) X
HIV, hepatitis B and C screen (per 
site SOP)X
UDS/BDS (per site SOP) X XScreening UDS/BDS is mandatory, any 
additional UDS/BDS are conducted per site 
SOP. UDS prior to randomization will be 
done on the day of admission.
Laboratory Safety Tests: 
(Hematology, Urinalysis, 
Chemistry)X X X X XCollected at predose (or equivalent) after ~[ADDRESS_952575]
AE/SAE review X X X X X X X X X XX X
Brief Psychiatric Rating Scale 
(BPRS)X X X X X up to [ADDRESS_952576]: MK-8189  28
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel C
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952577]-
studyScreening should occur within 6 weeks prior 
to Day 1
C-SSRS Baseline X up to 3 hours pre -dose Sec. [IP_ADDRESS] 
C-SSRS Since Last Assessment X X X X Xup to 3 hours pre- dose or equivalent Sec. 
[IP_ADDRESS] 
Barnes Akathisia Rating
Scale (BARS)f X X X X XUp to 3 hours pre- dose on dosing days. Any 
time on non -dosing days Sec.[IP_ADDRESS]
Abnormal Involuntary
Movement Scale (AIMS)f X X X X XUp to 3 hours pre- dose on dosing days. Any 
time on non -dosing days Sec.[IP_ADDRESS]
Simpson Angus Scale
(SAS)f X X X X XUp to 3 hours pre- dose on dosing days. Any 
time on non -dosing days Sec.[IP_ADDRESS]
Pharmacokinetics
Blood for Plasma MK -[ADDRESS_952578]: MK-8189  29
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Panel C
Study Period: Screening Washout InterventionPost-
study Notes
Scheduled Day Screening -[ADDRESS_952579]-
studyScreening should occur within 6 weeks prior 
to Day 1
ADA=antidrug antibody; AE=adverse event; BDS=blood drug screen; C-SSRS=Columbia-Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram; FBR=future biomedical research; FSH=follicle stimulating hormone; hCG= human chorionic gonadotropin ; ID=identification; SAE=serious adverse 
event; SOP=standard operating procedure; UDS= urine drug screen ; VS=vital signs; WOCBP=women of childbearing potential ; WONCBP=women of nonchildbearing 
potentia l.
a. Meals should be given at approximately the same time every day starting on Day -2 (Day -6 if washing off antips ychotic therapy) time-matched to postdose meals ,through 
Day 5. Breakfast will be given at ~1 hour postdose, lunch given at ~4 hours postdose, a snack given at ~8 hours postdose and dinner at ~12 hours postdose. All meals will 
follow the completion of all specified procedures at that timepoint
b. Participants will be confined minimally from Day -2until Day 6procedures are complete. If participant is washing off antipsychotic therapy domiciling will begin on Day -
6.
c. HR and BP, Day -1: Triplicate measurements in the supi[INVESTIGATOR_701710]-matched to 9hours post dose equivalent measurements . A single orthostatic assessment will be 
conducted following the last supi[INVESTIGATOR_701708].
• Single supi[INVESTIGATOR_701709]. On the following days, specific 
timepoints are noted;
• Days 1 -3: at 9hours post -dose
• Days 4-5: 9post-dose equivalent
• Days 6: Upon dis charge from the clinic
d. (24-hour) Holter ECG measurements will be performed from approximately [ADDRESS_952580]-dose.
ECG data will be extracted on:
• Day -1 (baseline measurement): time matched to dosing da ys at the following timepoints: 0.5hr, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 
• Day 1: predose, 0.5hr, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 hours postdose
• Day 2: predose, 1, 2, 6, 8, 10, 12, 14, 16 postdose
• Day 3: pre-dose, 1, 2, 6, 8, 10, 12, 14, 16, [ADDRESS_952581]- dose.In addition, Holter ECGs will be obtained 48 (Day 5) and 72 hours (Day 6) following the Day 3dose.
e. 12-lead safety ECG measurements. On the following days, specific timepoints are noted:
• Day -1: Triplicate measurements, Time -matched to 9hours post dose equivalent measurements
• Day 1 -3: at 9hours post -dose
• Day 4-5: at 9hours post -dose equivalent
• Days 6: Upon discharge from the clinic
f. Additional BARS, AIMS and SAS assessments should be conducted ifpossible when there are observed or reported complaints of dystonia and/or akathisia
g. MK-8189 plasma PK sample collection:
• Day 1: predose, 0.5hr, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16 hours postdose
• Day 2: predose, 1, 2, 6, 8, 10, 12, 14, 16 hours postdo se 
• Day 3: predose, 1, 2, 6, 8, 10, 12, 14, 16, 24, [ADDRESS_952582] -dose
• Leftover main study plasma will be stored for future biomedical research
h. Respi[INVESTIGATOR_170428]
i.       Participants should be encouraged to have periods of ambulation, o utside of the rest periods required prior to and during Holter extraction
All Panels/Periods
08D4MT
PRODUCT: MK-8189  30
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
2 INTRODUCTION
2.1 Study Rationale
This study is being conducted to support efforts to de -risk the potential for MK-8189 to 
prolong QT as required by [CONTACT_12212] E14.  Thus ,this study wi ll beconducted to 1)evaluate a 
supratherapeutic dose regimen in participants wi th schizophrenia to support, if required, a 
TQT in participants with schizophrenia and 2) perform a concentration- QTc analysis in 
partic ipants with schizophrenia receiving supratherapeutic doses such that the need for a 
TQT study may be negated.
To appropriately interrogate the potential for a drug to prolong QT, a TQT study requires the 
administration of a supratherapeutic dose that is expected to cover the high clinical exposure 
scenario ; this reflects the exposure of the drug when affected by t he intrinsic or extrinsic 
factor that causes the greatest increase in plasma concentrations.   Thus, this study will 
evaluate safety, tolerability, and PK of multiple oral doses of MK -8189 at doses that will 
result in concentrations that are greater to those expected when MK -8189 is co -administered 
with a strong CYP3A inhibitor (1.27- fold increase in Cmax) , the factor which is expected to 
cause the greatest increase in MK -[ADDRESS_952583] clinical dose evaluated in Phase 2B .  
Conducting TQT studies in participants with schizophrenia is challeng ing;thispatient 
population is expected to have several co -morbidities and concomitant therapy which could 
confound a QTc assessment. Thus ,to avoid confounding the QTc assessment ,patients would 
be required to wash off their stable regimen of antipsychotic therap yfor several weeks as 
well as other treatment sthat may affect heart rate and therefore QTc evaluation .  To ensure 
appropriate power and account for discontinuations, it is anticipated that approximately 100 
participants with schizophrenia would need to be enrolled. Therefore this study will also 
evaluate whether a concentration -QTc analysis could be conducted in a smaller number of 
participants (n=30) in a study of shorter duration than a TQT study would require. Thus one 
panel of participants will be esc alated over 3 days to 80mgof MK -8189 which may provide 
exposures approximately 2-fold peak concentrations following MK -8189 coadministration 
with strong CYP3A inhibitor at steady- state (high clinical exposure scenar io).  Achieving 
these exposures and assessing ECG parameter values, would support aconcentration- QTc 
assessment and de -risk the potential for MK -8189 to induce QT prolongation, even in the 
absence of a positive control ,which is required in a TQT study .  
2.2 Background
Refer to the IB/approved labeling for detailed background information on MK -8189.
2.2.[ADDRESS_952584]: MK-8189  31
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
The PDE10A enzyme metabolically inactivates the ubiquitous second messengers, cAMP 
and cGMP [Bender, A. T. and Beavo, J. A. 2006] and is highly expressed inthetarget
nucleus ofthecorticostriatal pathway, thestriatum [Seeger, T. F., et al 2003] .
Preclinical pharmacology studies demonstrate that PDE10A inhibition increases
cAMP/cGMP signaling in pathways that have been associated with un derlying pathology
(glutamate) aswell asclinically validated therapeutics (dopamine D2receptor antagonists) for 
schizophrenia. Enhanced signaling in these pathways is hypothesized to restore behavioral 
inhibition that is impaired in schizophrenia [Grauer, S. M., et al 2009] [Schmidt, C. J., et al 
2008] . PDE10A inhibitors may potentially be an alternative treatment as monotherapy and/or 
adjunc ttreatment in schizophrenia patients who have inadequate response to first line AAP
treatment.
2.2.2 Preclinical and Clinical Studies
Preclinical and clinical study information can be found in the MK -8189 IB .
Completed Phase 1 Clinical Studies:
As part of the Phase [ADDRESS_952585] one dose of MK- 8189; [ADDRESS_952586] been given to 48 healthy men; 22 
with an IR formulation and 26 with a CR formulation. Ten healthy male and female 
participants received multiple doses titrated up to 12 mg over 14 days (P003 Part 3) and 12 
healthy male and female participants received doses titrated up to 24 mg over 18 days (P007 
Panel A). Thirty -three male and female participants with schizophrenia were titrated up to 
doses of 16 mg over 14 days (P003), 25 participants with schizo phrenia were titrated up to 24 
mg over 18 days (P007 Panel B and C) and 17 participants with schizophrenia were titrated 
up to 48 mg over 15 days (P007 Panel D). All multiple -dose studies were conducted with a 
CR formulation.
Overview of Pharmacokinetics:
Following multiple doses of the controlled release formulation, MK- 8189 exposure increased 
approximately proportionally with dose over the range of doses tested (2 to 48 mg) in all 
populations. Median Tmax of MK- 8189 as monotherapy ranged from 10 to 24 hours with a 
t1/[ADDRESS_952587] that the 
exposures at steady state for a given dose are generally comparable between healthy 
participants and participants with schizophrenia administere d MK -8189 as monotherapy.
MK-8189 is a CYP3A substrate and in a DDI study (P006) the coadministration of extended 
release 240 -mg diltiazem, a moderate CYP3A inhibitor, increased MK -8189 AUC and Cmax 
by [CONTACT_3450] 2- fold and 1.3- fold, respectively .Preli minary data from an ongoing DDI 
study (P015, described in 2.2.3) demonstrated that coadministration of itraconazole, a strong 
CYP3A inhibitor, increased MK -[ADDRESS_952588]: MK-8189  32
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
data from anongoing hepatic impairment study (P012) demonstrated that MK-8189 AUC 
and Cmax were approximately 1. 18-fold and 1. 22-foldhigher in participants with moderate 
hepatic impairment compared to healthy matched controls , respectivel y.  Preliminary results 
from an ongoing study in adult and elderly (P011 )suggest that PK exposures in elderly 
participants with and wi thout schizophrenia are generally similar to one another and similar 
to those observed in adult participants < 60 years of age with schizophrenia. 
Overview of Safety:
MK-[ADDRESS_952589] common 
treatme nt-related adverse events [AEs] ( ≥5%) following treatment of MK -8189 (n=146) 
across the completed 6 Phase 1 studies in healthy participants and participants with 
schizophrenia were headache (16.4%) somnolence (12.3%), decreased appetite (10.3%), 
nausea (9.6%), fatigue (8.9%), dizziness (8.9%), vomiting (6.2%) diarrhea (6.2%), akathisia 
(6.2%), and anxiety (6.2%). Most AEs were mild to moderate in severity. There were no 
deaths and two SAEs. One participant experienced an SAE of gastroenteritis in P003 which
was not considered treatment related. The other SAE of psychosis occurred in a participant 
with schizophrenia in P007. Both SAEs are detailed in the IB. 
In a Phase 2 POC trial (P005), MK- [ADDRESS_952590] one dose of the once daily MK -8189 (titrated every 3 days from 4 mg 
to 8 mg and 12 mg, as tolerated). Participants were dosed after they were able to taper off 
psychotropic medications. Adverse Events that occurred in ≥5% of participants in the
MK-8189 intervention group and had greater incidence than placebo were diarrhea, nausea, 
vomiting, decreased appetite, akathisia, dystonia, headache, sedation, somnolence, anxiety, 
and insomnia. No deaths were reported in the P005 study. No SAEs were repo rted for 
participants on MK -8189. Eight participants [8.9%]) had an AE of dystonia and 2 
participants (2.2%) had an AE of oromandibular dystonia. 
Detailed PK and safety information from individual completed studies are summarized in the 
IB.
2.2.3 Ongoing Clinical Studies
As of 14 -February- 2022, three Phase 1 trials and one Phase 2 trial are ongoing. All data 
presented are preliminary. 
[IP_ADDRESS] Protocol 011
P011 is a Phase 1 multiple -dose, randomized, double -blind, placebo- controlled, multicenter, 
2-part study. Par t 1 (Panel A/B/C) evaluated the safety and tolerability of different titration 
regimens (including without titration) in participants ≤60 years of age with schizophrenia. 
Part 1 is clinically complete and all data are preliminary and blinded. Panel C was n ot 
conducted per protocol since the regimens in Panel A and B were generally well tolerated. 
Part 2 is evaluating the safety, tolerability, and PK of MK- 8189 in elderly participants with 
schizophrenia and healthy elderly participants between 61 and 80 year s of age (inclusive). 
All data presented are blinded.
08D4MT
PRODUCT: MK-8189  33
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
In Part 1, Panel A, participants with schizophrenia initiated dosing with 16 mg of 
MK-8189/placebo for 3 days, then escalated to 24 mg/placebo for [ADDRESS_952591] AEs were mild, and no SAEs or deaths were 
reported. All AEs resolved. Of the 8 participants, one participant did not dose escalate to 24 
mg/placebo due to moderate somnolence which lasted for [ADDRESS_952592] dose and lasted 2 days. The dystonia was 
treated with benztropi[INVESTIGATOR_100883]. The participant continued dosing with 
MK-8189/pl acebo without recurrence of dystonia. Another participant reported mild transient 
dystonia which began 6.[ADDRESS_952593] dose, was treated with benztropi[INVESTIGATOR_701711] 22 hours. The participant continued in the study and escalated to 24 mg/placebo 
without a recurrence of dystonia. AEs reported (including those already discussed) 
considered related to study drug included decreased appetite (n=2), dystonia (n=2) 
somnolence (n=2), nightmare (n=1), worsening psychosis (n=1), and insomnia (n=1).
In Panel B, participants with schizophrenia were dosed with 24 mg of MK -8189/placebo (no 
titration) for 7 days. In Panel B, enrollment and dosing are complete. Eighteen participants 
were randomized and 14 completed treatment per protocol. Of the 4 particip ants that 
discontinued treatment, 3 withdrew consent and 1 participant discontinued due to AEs of 
nausea and vomiting that were not considered related to treatment. No AEs were considered 
severe and the majority of AEs were mild. Except for an unrelated AE of ligament sprain, all 
AEs resolved. AEs considered related to treatment included somnolence (n=2), hypertonia 
(n=1), decreased appetite (n=1), musculoskeletal stiffness (n=1) and increased ALT (n=1). 
No AEs of akathisia or dystonia were reported.
Treatm ent is ongoing in Part 2. Panel D is currently enrolling elderly participants with 
schizophrenia. Participants will receive MK -8189 8 mg/placebo Days 1 -3, MK -8189 16 
mg/placebo Days 4 -6 and MK -8189 24 mg/placebo Days [ADDRESS_952594] AEs 
were mild or moderate; 1 AE was severe (described below). All AEs reported to date have 
resolved except an AE of a small forehead bump considered not treatment related. Five 
participants have discontinued the trial: Two participants withdrew consent. One participant 
reported an AE of severe somnolence which began following the 8 mg/placebo dose and 
resolved on Day 3. On Day 3 following treatment with 8 mg/placebo, the same partic ipant 
had an AE of moderate dystonia which resolved in 2 days with a single dose of 
cyclobenzaprine. This participant also reported moderate akathisia following treatment with 
8 mg/placebo which continued for 3 weeks. This participant had drug interrupted and 
subsequently discontinued following the second 16 mg/placebo dose due to moderate 
treatment -related AEs of rash and conjunctivitis. 
One participant experienced dystonia of the throat after the Day 3 16 mg/placebo dose which 
was treated with benztropi[INVESTIGATOR_050]. Tightness of the throat muscles which the investigator 
considered to be mild dystonia persisted for [ADDRESS_952595]: MK-8189  34
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952596] dose of 24 mg/placebo. 
As of the cut- off date, t his panel wasactively dosing and the following treatment related AEs 
have been reported to date (includes AEs which have been reported above); dystonia (n=2), 
internal restlessness (n=2), somnolence (n=1), akathisia (n=1), conjunctivitis (n=1), rash 
(n=1), dizziness (n=1), dysgeusia (n=1), ear discomfort (n=1), oral hypoesthesia (n=1) and 
involuntary movement of lower extremities (n=1).
Panel F is clini cally complete and enrolled [ADDRESS_952597] 
been repo rted. Except for hyponatremia (discussed below), all other reported AEs resolved. 
One subject discontinued the trial due to treatment related AEs of nausea, vomiting, 
dyspepsia, and hyponatremia. This participant also reported diarrhea prior to the onset o f 
nausea and vomiting. The hyponatremia was ongoing at the time of participant discharge. 
One participant was down- titrated from 24 mg/placebo to 16 mg/placebo following the onset 
of moderate EPS. The EPS had a duration of approximately 2 weeks and was man aged 
intermittently with benztropi[INVESTIGATOR_050]. This participant completed treatment and the study. The 
treatment -related AEs reported (including those discussed above) were decreased appetite 
(n=1), dizziness (n=1), nausea (n=1), vomiting (n=1), dyspepsia (n=1), hy ponatremia (n=1), 
somnolence (n=1), involuntary muscle contractions (n=1), tremor (n=1), extrapyramidal 
disorder (n=1) and salivary hypersecretion (n=1).
Panel G completed dosing in healthy elderly participants. Participants received MK- 8189 16 
mg/placebo Days 1 -3, MK -8189 24 mg/placebo Days [ADDRESS_952598] AEs were mild. Three AEs were severe (2 participants with severe 
somnolence and 1 participant with severe hypnagogic hallucination) and are described 
below; no deaths or SA Es were reported. All AEs resolved. Three participants discontinued 
due to treatment related AEs. Beginning on the evening of Day 7, following 2 days of dosing 
with MK -8189 24 mg/placebo, one participant reported mild akathisia (~20 hour), moderate 
tactile hallucinations (15 min), mild palpi[INVESTIGATOR_814] (2 min) and bilateral hand hyperhidrosis 
(5hour) and severe hypnagogic hallucinations (5 min). The participant reported these AEs on 
the morning of Day 8, the dose was held, the participant received treatment with benztropi[INVESTIGATOR_701712]. Later in the afternoon of Day 8, the participant had a recurrence of 
akathisia, bilateral hand hyperhidrosis, tactile hallucinations and reported sinus tachycardia, 
all which resolved with benztropi[INVESTIGATOR_050]. The participant d iscontinued treatment due to these 
AEs. This participant also had a brief epi[INVESTIGATOR_1865] (~30 min) of mild oral mandibular dystonia on 
Day 1 (16 mg/placebo) that resolved spontaneously.
Another subject discontinued due to an AE of mild akathisia (~24 hour) follow ing a 16 
mg/placebo dose on Day [ADDRESS_952599]: MK-8189  35
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952600] discontinued after 2 days of dosing at the 24 mg/placebo dose (Day 5) due to 
moderate oromandibular dystonia (~6 hours) and moderate anxiety (<24 hours duration); 
both AEs resp onded to treatment. 
Two participants were reported to have severe somnolence. In both participants the 
somnolence began within [ADDRESS_952601] dose of study intervention (16 mg/placebo) 
and resolved in ≤ 10 hours. All treatmen t-related AEs reporte d (including those discussed 
above) were somnolence (n=4), akathisia (n=3), oromandibular dystonia (n=2), myalgia 
(n=2), tremor (n=2), headache (n=2), involuntary muscle contractions (n=2), tactile 
hallucination (n=1), palpi[INVESTIGATOR_814] (n=1), bilateral hand hy perhidrosis (n=1), hypnagogic 
hallucination (n=1), sinus tachycardia (n=1), restlessness (n=1), dyspepsia (n=1), vomiting 
(n=1), paresthesia (n=1), insomnia (n=1), apathy (n=1) dysphonia (n=1), salivary 
hypersecretion (n=1), anxiety (n=1), bilateral hands rapid alternating movements (n=1) and 
smell sensitivity (n=1).
[IP_ADDRESS] Protocol [ADDRESS_952602] been reported. The following treatment related AEs 
(duration) have been reported by 4 participants: One participant had mild AEs of a hot flush 
(40 min), vomiting (1 epi[INVESTIGATOR_1865]) and leg cramps (10 min). One participant had a mild AE of 
dizziness (<1 day). One participant had mild AEs of headache (<1 day), anxiety (30 min) and 
affect lability (30 min).
[IP_ADDRESS] Protocol [ADDRESS_952603] one AE considered related to MK -8189 and/or itraconazole (duration). One 
participant discontinued due to AE of mild rash (2 days) to itraconazole. In Period 1 on Day 
1, one participant reported mild AEs of somnolence (1 day) and diz ziness (8.5 hours) 
considered related to MK -8189. In Period 2 on Day 4, this same participant reported mild 
restlessness (20 hours) and an ECI of dystonia (12 hours) of moderate severity considered 
related to MK -8189 and itraconazole. The dystonia resolved without treatment. Following a 
blood draw, two other AEs, mild pre -syncopal event (5 min) and mild faint sensation (12 
min), were also reported by [CONTACT_701721]. One other participant reported a n AE of mild dystonia (~ 2 days) which began 
in Period 2 on Day 5. The dystonia resolved without treatment and was considered related to 
MK-8189 and itraconazole. One participant had mild AEs of somnolence (2 days) and 
diarrhea (9 days). The somnolence beg an in Period [ADDRESS_952604]: MK-8189  36
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
considered related to itraconazole. Three other participants reported mild diarrhea (5 hours, 3 
days and 6 days) which b egan in Period 2 prior to MK 8189 administration.
[IP_ADDRESS] Protocol 013
P013 (non-IND study) is a multiple ascending dose, randomized, double -blind, placebo-
controlled (3:1) parallel -group study being conducted in China to evaluate the safety, 
tolerability, and PK of MK- 8189 titrated from 8 mg to 24 mg in healthy Chinese participants 
(n=16). P013 was clinically complete as of the cut -off date. All data presented are blinded.
There were no SAEs or deaths reported. One participant discontinued due to an AE of 
moderate delusion with a duration of 15.[ADDRESS_952605] dose of MK- 8189 8 
mg/placebo. This participant also had the following AEs (duration): mild somnolence on 2 
occasions (6 hours and 18.5 hours), moderate depressed mood (3 days), mild dystonia (7. 5 
hours), and mild insomnia on two occasions (7.5 hours and 4 days).
One participant reported an AE of suicidal ideation without intent which lasted for 5 seconds 
following their second dose of 24 mg/placebo: It was reported that after a dream the 
partici pant had mood swings and was crying. The concept of transient suicide appeared. He 
was observed during the clinical course. The subject did not receive treatment for the event. 
The participants mood AE resolved in [ADDRESS_952606] dose of 24 mg of MK -8189/ placebo per protocol. The investigator considered 
suicidal ideation (mild) to be related to study intervention. This subject also reported AEs 
(duration) of mild headache (3 hours), mild somnolence (18.5 hou rs), mild cognitive disorder 
(16 hours), mild anxiety (14 hours), mild tremor (12 hours) following the first dose of 8 
mg/placebo, mild ventricular tachycardia (1.3 weeks) with ventricular rate ranging from 62 to 
78 bpm (Screening ventricular rate was 75 bpm), mild increased total bilirubin (also elevated 
at Screening) with direct bilirubin within the normal range (3 weeks) following their second 
12 mg/placebo dose, mild unrelated pharyngeal swelling (9 hours) following their second 16 
mg/placebo dose, mild insomnia (5 days) two days following their last 24 mg/placebo dose, 
mild hyperphosphatemia (1.7 weeks), mild hypercalcemia (also elevated at Screening) (1.7 
weeks) three days following their last 24 mg MK- 8189/placebo dose.
The most frequently reported tr eatment related AEs (N ≥2) were somnolence (N=12), 
insomnia (N=10), decreased appetite (N=5), dystonia (N=5), nausea (N=5), akathisia (N=3), 
anxiety (N=3), tremor (N=3), blood bilirubin increased (N=2), delusion (N=2), headache 
(N=2), hyperhidrosis (N=2) a nd vomiting (N=2). The majority of AEs reported were mild 
and no AEs were severe. The AEs of akathisia, dystonia, delusions, and most AEs of anxiety 
and somnolence resolved within a few hours. Most of these AEs resolved spontaneously and 
only one AE of dystonia, anxiety and akathisia were treated. One participant had moderate 
depressed mood beginning with the 8 mg/placebo dose which resolved within 3 days with 
continued dosing. Other mood AEs resolved within hours with continued dosing. 
[IP_ADDRESS] Protocol [ADDRESS_952607]: MK-8189  37
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
titrated from 8 mg to 72 mg in 25 healthy participants. Participants were administered the 
following dose regimen; 8 mg/placebo Day 1, 16 mg/placebo Day 2, 24 mg/placebo Day 3, 
48 mg/placebo Day [ADDRESS_952608] dose 
of 72 mg due to tolerability issues. Per protocol , if 4 participants randomized to MK -8189
didnot dose escalate the stoppi[INVESTIGATOR_701713] . Though 
the trial remained blinded, conservatively it was decided to stop the trial and therefore no 
further participants were dosed. Two participants did not dose escalate fr om 48 mg/placebo 
to 72 mg/placebo and discontinued treatment due to mild and moderate adverse events of 
vomiting following their second dose of 48 mg. One of these participants also discontinued 
treatment due to moderate anxiety (9 hours) following their s econd dose of 48 mg/placebo. A 
third participant was down- titrated following their first dose of 48 mg to 24 mg due to 
moderate somnolence ; the somnolence resolved prior to the 24 mg dose administration. A 
fourth participant discontinued treatment followin g their 24 mg/placebo dose due to severe
akathisia (duration 22.5 hours )and moderate affect lability which began after the 16 
mg/placebo dose (4 days) .After the 72 mg dose, one participant reported mild dystonia on 
one occasion lasting 17 minutes. One other participant reported a mild AE of oral dyskinesia 
following the 16 mg dose which lasted for 3 hours. Another participant reported intermittent 
mild akathisia after administration of the 72mg dose. The majority of AEs were mild and 
only one severe AE (akathisia described above) was reported. AEs reported by [CONTACT_701722]: nausea (n=7), decreased appetite (n= 6), 
headache (n=5), nightmare (n=4), insomnia (n=4), restlessness (n=3), leukocyturia (n=3) , 
dizziness (n=2), hematuria (n=2), palpi[INVESTIGATOR_814] (n=2), diarrhea (n=3), dyspepsia (n=2), 
eructation (n=2), pyuria (n=2), systolic blood pressure increased (n=2), muscle spasms (n=2), 
myalgia (n=2), akathisia (n=2), somnolence (n=2 ), vomiting (n=2 )andaffect lability (n=2) .
With the exception o f a poststudy unrelated AE of leukocyturia in one participant , all other 
AEs resolved. Administration of MK -8189/placebo up to 24 mg was generally well tolerated.
The aggressive titration regimen above 24 mg was not generally well tolerated in healthy 
participants.
[IP_ADDRESS] Protocol 008
P008 is an ongoing Phase 2B randomized, double -blind, placebo- and active controlled trial 
of the efficacy and safety of MK- 8189 in adult participants 18 to 50 years of age who are 
experiencing an acute epi[INVESTIGATOR_326620] -V™ criteria. 
A total of 576 participants from approximately 80 sites across the [LOCATION_003], Europe and Asia will 
be recruited into this trial. Recruitment was initiated in December 2020. Treatment duration 
will be for a period of 12 weeks and includes a 6- week acute treatment period followed by a 
6-week extension period. Eligible participants will be randomized to receive one of five 
treatment sequences with target doses of MK -8189 (8 mg, 
16 mg, and 24 mg QD), 
risperidone (6 mg QD), or placebo. Placebo completers at 6 weeks will be allocated to 
receive MK -8189 24 mg for the remainder of the trial. This trial is being conducted in a 
hospi[INVESTIGATOR_307]/acute care setting followed by [CONTACT_701723].
08D4MT
PRODUCT: MK-8189  38
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
2.2.4 Information on Other Study -related Therapy
Not applicable .
2.3 Benefit/Risk Asse ssment
Participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safety and 
properties of an investigational medicine. 
Additional details regarding speci fic benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
Hypotheses are aligned with objectives in the Objectives and Endpoints ta ble.
The following objectives will be evaluated in male and female participants with 
schizophrenia:
Objectives Endpoints
Primary
•To evaluate the safety and tolerability of 
multiple ascending doses of MK -8189 in 
participants with schizophrenia•Adverse events , discontinuation of 
study intervention due to adverse 
events
Secondary
•Not applicable •Not applicable
Tertiary/Exploratory
•To estimate the pharmacokinetics of MK -
8189 following multiple ascending doses 
of MK -8189 in partic ipants with 
schizophrenia•AUC0 -24, Cmax, C24, AUC0 -inf,
Tmax, CL /F, Vz/Fand apparent t1/2
•To evaluate the effect of MK -8189 
concentrations on QTc interval and ECG 
parameters in participants with 
schizophrenia•QTc, PR and RR intervals, heart rate, 
QRS duration, T wave morphology, 
presence of U waves and outlier 
assessmen t
08D4MT
PRODUCT: MK-8189  39
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Objectives Endpoints
•To investigate the relationship between 
the genetic polymorphisms of CYP2C9 
and the pharmacokinetics of MK -8189. 
Variation in CYP2C9 alleles may be 
analyzed for association with any 
laboratory or clinical data collected in this 
study.•Germline genetic variation in CYP2C9 
and association to clinical data 
collected in this study
4 S TUDY DESIGN
4.1 Overall Design
This is a randomized, placebo -controlled, parallel- group, multisite, double -blind ,multiple -
panel study of MK -8189 in participants with schizophrenia .
Panels A and A -1will enroll up to 12participants each with schizophrenia (9 on active and 
3on placebo) .Participants will be randomized to receive orally administered risi ng-doses of 
MK-8189 or placebo. For Panel A ,participants will receive MK-8189 48 mg/placebo Day 1, 
MK-8189 60 mg/placebo Day 2. For Panel A -1,participants will receive MK-8189 
48mg/placebo Day 1, MK -8189 8 0 mg/placebo Day 2.
Panel C will initiate if the dose regimen in Panel A and Panel A-1 arefound to be generally 
well tolerated. Panel C will enroll up to 30 participants with schizophrenia (18 on active and 
12 on placebo) . Participants will be randomized to receive orally administer ed rising -doses of 
MK-8189 or placebo; MK -8189 48 mg/placebo Days 1 -2, MK -8189 80 mg/placebo Day 3.
Following completion of dosing in each Panel A andPanel A -1,the decision on which dose 
regimen to evaluate next per Figure [ADDRESS_952609]: MK-8189  40
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Figure 2Study Design – Decision Tree
If applicable, participants will be washed off their current antipsychotic therapy.  The 
washout may start with a down titration of the antipsychotic treatment during the screening 
phase per direction of the investigator.  Participants should not receive antipsychotics for at 
least 5 days or 3 half -lives (whichever is longer) prior to Day - 1.  For longer half -life 
antipsychotics ( eg,aripi[INVESTIGATOR_123636]), if deemed appropriate by [CONTACT_1275], a participant may stop treatment ( ie,cessation of atypi[INVESTIGATOR_628542]) 
as an outpatient, but should be confined to the clinical research unit within a week of 
stoppi[INVESTIGATOR_701714] -6.  If participants are not currently 
receiving antipsychotic therapy, they will be domiciled beginning on Day -[ADDRESS_952610] of care may be restarted. At the 
investigator’s discretion, the parti cipant may be domiciled for a longer duration if up titration 
is observation is required.
08D4MT
PRODUCT: MK-8189  41
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Titration will occur per the investigator’s medical discretion based on the tolerability of 
MK-8189 within an individual participant. Anytime during the dose escalati on, if the 
investigator deems it necessary, dose escalation within an individual may be paused 
temporarily for the duration of any tolerability issues involved and resumed immediately at 
the next dose level .Any changes to the dose regimen will not prolong an individual’s 
participation in the trial and therefore it is acknowledged that failure to adhere to the 
protocol -defined titration regimen may result in some participants not reaching the escalation 
targe ts.Regardless of the state of the dose escalatio n of each participant it is important to 
keep participants in the study as the data collected at all doses could still be valuable for the 
purposes of defining a clinical tolerability margin .In Panel C , the 24 -Holter extraction and 
PK sampling will not be repeated within an individual at the same dose level. Any changes to 
the protocol specified treatment regimen will be documented in a Protocol Clarification 
Letter.  
Because this is a Phase 1 assessment ofMK-8189 in humans, the PK, pharmacodynamic, and 
safety profiles of the compound are still being elucidated. This protocol is therefore written 
with flexibility to accommodate the inherent dynamic nature of Pha se 1 clinical studies. 
Refer to Section 8.11.6 for examples of modifications permitted within the protocol 
parameters.
Specific procedures to be performed during the study, including prescribed times and 
associated visit windows, are outlined in Section 1.3 of the SoA. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
The adaptive nature of this study design allows for the exploration of thesafety and
tolerability of multiple ascending dose regimens to support both a TQT study (Panels A, A-1 ) 
and concentration- QT analysis (Panel C) . This study will allow for the selection of the 
optimal dose -regimen for a TQT study.  To support a TQT study, the dose evaluated should 
achieve peak concentrations that are approxi mately 2-fold the steady- state Cmax following 
administration of the highest clinical dose of MK- 8189.  Titration within an individual per 
protocol will be based on the tolerability profile (AE data) and will be at the discretion of the 
investigator. Prior to this amendment, Panel A was complet ed. Eleven participants were 
enrolled and allcompleted treatment per protocol and the dose regimen was found to be well 
tolerated. Preliminary PK analysis from this p anel showed exposures were not sufficient to 
support a TQT study; mean peak concentrations approximated only 1.7 -fold the predicted 
steady- state Cmax following administration of 24 mg vs the required 2 -fold multiple. As 
such,this amendment is including Panel A -1 to evaluate the safety, tolerability, and PK of 
MK-8189 48 mg administered on Day 1 and 80 mg administered on Day 2.
In order for concentration- QT analysis (Panel C) to negate the need for a TQT study, key 
elements must be included in the study design including 1) administration of a dose that 
provides concentrations that are at least 2-fold those observed at the highest clinical dose 
when administered under conditions where exposures are expected to maximally increase.  In 
the case to MK- 8189, this scenario would be co -administration of MK -8189 with a CYP3A 
inhibitor, which results in a 27% increase in peak concentrations. 2) a sufficient sample size 
08D4MT
PRODUCT: MK-8189  42
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
(evaluable data from 12 active and 8 placebo) and 3) robust ECG assessments time -matched 
to PK assessments.  In addition, if an exposure of 2- fold the high clinical exposure scenario 
cannot be achieved, a lower exposure multiple may be acceptable if non -clinical data also 
support the lack of a QT effect at sufficient margins to the clinical dose (ICH E14 and S7B 
Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhy thmic 
Potential -Questions and Answer -Guidance for the Industry August 2022 (Final)) [European 
Medicines Agency 2022] . Thus, in Panel C , this study will collect Holter recordings for [ADDRESS_952611] dose to assess the ECG parameter intervals across a wide range of conce ntrations . 
Replicate ECGs and central core lab assessments are incorporated in the design to asses s 
ECG intervals with reduced variability. The PK assessments on the same days/timepoints 
will facilitate further exploration of temporal and concentration dependance on ECG 
parameters.
As all participants are domiciled throughout the trial, there is adequ ate monitoring for any 
safety concerns and participants will be continued to be domiciled for [ADDRESS_952612] dose of study intervention. Thus, the sponsor feels the evaluation of a dose regimen to 
support a TQT study or concentration- QT analys iscan be evaluated safely.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
Not Applicable
[IP_ADDRESS] Safety Endpoints
Safety and tolerability will be assessed throughout the study by [CONTACT_326640], physical exams, ECGs, 
VS, and laboratory safety tests. The C -SSRS will be administered to monitor mood and 
suicidal ideation and behavior in all trial participants (see Section 4.2. ).In addition, scales 
will be included to evaluate EPS and general well -being.
As EPS are associated with antipsychotics and have been observed in the MK -8189 clinical
program, the BARS, AIMS and SAS will be used to quantify any EPS observed in the study.
The BARS is an akathisia rating scale with objective and su bjective measures and an overall
rating from 0 to 5. A score of 0 presents no evidence for akathisia, a score of 3 is moderate
akathisia and a score of 5 is severe akathisia. The AIMS evaluates 12 items and uses a 5 -
point scale to assess abnormal movement in 3 areas (orofacial, extremities, trunk). The SAS
evaluates 10 items and uses a 5- point scale to measure symptoms of parkinsonism or
parkinsonian side effects (including rigidity, tremor, akinesia, and salivation).
In case moderate EPS symptoms in an individual participant persist, the dose will not be
further up titrated for this participant. Participants with severe EPS symptoms will be
discontinued if not attenuated with dose reduction, dose titration and/or medical
management.
08D4MT
PRODUCT: MK-8189  43
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
The BPRS rating scale w ill be used to measure psychiatric symptoms such as depression, 
anxiety, hallucinations and unusual behavior in a range of psychotic and affective symptoms 
in participants with schizophrenia.  The BPRS has been used in clinical research as a tool to 
measur e treatment effects and are effective scales to monitor the general well- being of the 
psychiatric patients. The BPRS consists of 18 symptom constructs and takes 20 to 30 minutes 
for the interview and scoring. The rater should enter a number ranging from 1 (not present) to 
7 (extremely severe). Zero is entered if the item is not assessed. Participants who experience 
severe psychosis during the study will be discontinued and referred for additional treatment 
as indicated.
[IP_ADDRESS] Pharmacokinetic Endpoints
An objecti ve of this study is to characterize the PK of MK- 8189. Therefore, individual 
plasma concentration and actual sample collection times of MK -8189 will be used to derive 
the PK parameter values AUC0 -24, Cmax, Tmax, C24, CL/F, Vz/F ,and apparent t1/2.
[IP_ADDRESS] Pharmacodynamic Endpoints
An exploratory objective of this trial is to evaluate effects of a supra -therapeutic dose of MK -
[ADDRESS_952613] of a drug on 
cardiac repolarization can be measured as prolongation of the QT interval on ECG 
recordings. There is, in general, a qualitative relationship between substantial QT 
prolongation and the risk of TdP. The rationale for the endpoint is thus to demonstrate that 
MK-8189 does not meaningfully prolong (i .e. >10 msec) the QTc interval.
In Panel C, electrocardiogram data ( eg,QT, QRS, RR and PR intervals) will be obtained with 
a digital Holter device on study days specified in the SoA.  A [ADDRESS_952614]-dose assessments as specified in the SoA.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_952615] a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug ADME ; mechanism of action of the drug; disease etiology; and/or 
molecular subtype of the disease being treated. Therefore, where local regulations and 
IRB/IEC allow, a sample will be collected for DNA analysis from consenting participants.
DNA samples may be used for research related to the study intervention( s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of [ADDRESS_952616]: MK-8189  44
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
The samples may be analyzed as part of a multistudy assessment of genetic factors involved 
in the response to understand study disease or related conditions.
In addition to studying variation across the human genome CYP2C9 will specifically be 
investigated for association with the PK and PD endpoints of MK -8189 since MK -8189 is 
partially metabolized by [CONTACT_097]2C9. Genetic variation in CYP2C9 may be analyzed for 
association with any laboratory or clinical data collected in this study.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on spec imens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene expression profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR .
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of coll ecting/retaining specime ns for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure tha t participants receive the correct dose of 
the correct drug/vaccine at the cor rect time. The details of FBR r esearch are presented in
Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
As the safety and tolerability profile is under continued evaluati on and limited data is 
available at higher doses of MK -8189, a placebo- control will be included in this trial to 
ensure objective assessment of AEs. A placebo arm is also required to support the 
concentration- QTc analysis and helps to avoid false positive and false negative results; in
some instances study conditions have been found to prolong or shorten QT and placebo -
correction is required to determine the true effect of the drug.
4.2.3 Rationale for Suicidal Ideation and Behavior Monitoring
Prospective assessment of suicidal ideation and behavior will be performed in this study 
using the C -SSRS. This assessment is being conducted in compliance with the 2012 FDA 
guidance requiring prospective assessment in cl inical studies conducted under IND 
applications and studies that ar e intended for submission in a NDA to the Neurology or 
Psychiatry Divisions of the FDA or BLA , as well as assessment in studies that fall within the 
guidance for other reasons (eg, CNS active/penetrant compounds, and known mechanisms or 
indications for which suicidal ideation/behavior has been previously identified as a potential 
concern).
4.[ADDRESS_952617]: MK-8189  45
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
regimen may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants. Details of allowed 
modifications are provided in Section 8.11.6.
4.3.1 Starting Dose for This Study
In Panel A , A-1 and C, the starting dose will be MK-8189 48 mg/p lacebo .  A starting dose of 
24 mg/placebo was well tolerated in participants with schizophrenia in P011 (Section 2.2.3)
Multiple doses of 48 mg (3 consecutive days) have been evaluated in participants with 
schizophrenia in P007 ,a multiple ascending dose study. In P007, participants were titrated 
from 8 mg to 48 mg.  There were no clear trends for dose related increases in specific AEs 
and the 48 mg dose was found to be generally well tolerated. The majority of AEs were mild 
to moderate in severity.  Adverse events (n, %) occurring in more than one participant were 
dizziness ( 3, 27%), nausea (2, 18%) and anxiety (2, 18%).  One of the AEs of anxiety was 
considered severe and unrelated to study intervention. The AE began one day aft er the last 
dose of MK- [ADDRESS_952618] oration of a 48 
mg starting dose in the current protocol . Panel C will only be conducted if the starting dose 
of 48 mg in Panel A is generally well tolerated.
Preliminary blinded data from Panel A demonstrated good tolerability of MK -8189 
48mg/placebo adm inistered on Day 1 and MK -8189 60 mg/placebo administered on Day 2. 
There were no deaths or SAEs. Four of the 11 participants reported 5 AEs of mild severity. 
The following treatment -related AEs (duration) were reported; discomfort (3 days), leg 
tremor (2. 5 weeks) and headache (2 days). There were no trends for clinical meaningful 
changes in safety laboratory values, VS , or ECGs.
4.3.2 Maximum Dose/Exposure for This Study
The highest dose evaluated in this study will be [ADDRESS_952619] dose evaluated was 72 mg/placebo 
(n=8) in P016 (see section 2.2.3 .6). Data from P016 are preliminary and blinded. InP016, 
poorer tolerability was obse rved in some participants at the 48 mg dose such that 4 of 12 
participants on MK -8189/placebo did not dose escalate above 48 mg) . The tolerability issues 
may have been due to the rapid titration above 24 mg/placebo in Protocol 016.  Of the 8 
participants that dose escalated to 72 mg/placebo, 5 reported AEs.  The majority of AEs were 
mild in severity.  Adverse events included: nausea (n=2), nightmare (n=1) , insomnia (n=1), 
tremor in legs (n=1), muscle twitches (n=1) , dystonia (n=1), staring (n=1), decreased appetite 
(n=1), headache (n=2), xerostomia (n=1), hot flashes (n=1), closed eye hallucination (n=1), 
pyrosis (n=1), muscle spas ms (n=1), emotional instability (n=1), globus pharynges (n=1), 
hoarseness (n=1), akathisia (n=1).   As all AEs are monit orable and reversible, escalating to 
[ADDRESS_952620]: MK-8189  46
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Moreover, across the multiple ascending dose studies (P003, P007 and P011), there was no 
dose relationship for specific AEs, including akathisia, somnolence, anxiety, nausea and 
vomiting.
The 80mg dose was previously predicted to provide exposures 2 -fold the high clinical 
exposure scenario ( the highest possible clinical dose of MK -8189 coadministered with a 
strong CYP3A inhibitor) a nd support a concentration -QTc analysis that could negate the 
need for a much larger TQT study in patients. However, preliminary PK data from Panel A 
following a [ADDRESS_952621] that sufficient exposures may not be achieved 
following an 80-m g dose . However , exposures following an 80 mg, or lower dose if 80 mg is 
not generally well tolerated in Panel A -1, may be sufficient to support an integrated waiver 
assessment per ICH E14 &S7B Q&A [European Medici nes Agency 2022] .
The predicted exposure at 80 mg is 71. 5μM∙hr and the margin to the AUC 0-24 for an 80 mg 
dose, as derived from the 6 -Week and chronic toxicology studies, would be 5 -12X and ~2 
fold, respectively, further supporting evaluation of this supratherapeutic dose.  Brief 
summaries of the 6- Week and chronic toxicology studies supporting dose escala tion are 
provided below:
In the 6 -Week rat study, doses of 25, 50 and 1000 mg/kg/day of MK -8189 were evaluated.  
There were no adverse findings in the study; therefore ,the no observed adverse effect level 
(NOAEL) was 1000 mg/kg/day (12 -fold in females (AU C0-24hr = 822 ∙hour) and 9 -fold in 
males (AUC 0-24hr = 653 ∙hour) over the predicted supratherapeutic exposure of 71. 5μM∙hr 
at the 80 mg dose).  The functional observational battery (FOB) evaluation conducted on 
Study Day [ADDRESS_952622]: MK-8189  47
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
decreases in mean body temperature. In addition, an absence of motor activity (akinesis) was 
noted in 1 of the 6 high -dose a nimals tested. Collectively, these observations are consistent 
with mild sedation. Importantly, these animals retained normal ability to respond to external 
stimuli as evidenced by [CONTACT_326641], touch and approach stimuli. These 
findings w ere considered transient as they were not present before the subsequent dose on 
Study Day 2.
In the 6 -Week monkey study, doses of 10, 30 and 300 mg/kg/day were administered.  
Pharmacologically- mediated physical signs were observed across all dose groups an d 
consisted of somnolence, increased/decreased activity, unsteady gait, increased 
licking/chewing/chompi[INVESTIGATOR_326623], vocalization, intermitted recumbency, intermitted whole 
body trembling, and/or salivation.  These physical signs were considered transient, r eversible 
and consistent with the expected pharmacology of PDE10A inhibition.  The NOAEL in this 
study was 300 mg/kg/day (AUC 0-24hour = 333 ∙hour) providing an exposure margin of 5 
fold over the predicted supratherapeutic exposure of 71. 5μM∙hr at the 80 mg dose.    
In the 6 month rat study, doses of 0, 25, 100 and 750 mg/kg/day were evaluated.  Two high 
dose (750 mg/kg/day) female rats were found dead (study week 13 and study week 24) with 
acute tubular necrosis (with and without tubular mineralization) .  Therefore the 100 
mg/kg/day dose was considered the no observed adverse effect level (NOAEL) for this study 
(AUC 0-24hr = 130 μM ∙hr), providing an exposure margin of 2 -fold over the predicted 
supratherapeutic exposure of 71. 5μM∙hr at the 80 mg dose.
In the 9 month monkey study, doses of 0, 30/10/3, 150 or 600/300 mg/kg/day of MK 8189 
were administered. Similar to the 6 -Week study, pharmacologically -mediated transient and 
reversible physical signs were observed in all dose groups in the study.  In additio n, 
beginning in Study Week 8 of this study, reversible physical signs of uncoordinated 
movements were observed down to the low -dose level.  Due to the severity of the 
uncoordinated movements, the low -dose level had to be lowered (30 to 3 mg/kg/day) to 
increase tolerability of the test article.  Based on these findings, the NOAEL for physical 
signs was <3 mg/kg/day. Renal tubular degeneration was observed in the high -dose group 
(600/300 mg/kg/day).  The NOAEL for target organ toxicity is 150 mg/kg/day (AUC 0-24hr = 
170 μM ∙hr), providing a 2 -fold over the predicted supratherapeutic exposure of 71. 5μM∙hr at 
the 80 mg dose.
The effects of MK- 8189 on measures of cardiac conduction and repolarization were assessed 
in both in vitro (hERG current [IKr] evaluation) a nd in vivo (anesthetized guinea pi[INVESTIGATOR_701715]). MK- 8189 inhibited hERG current with an IC50 
value of 81.9 μM, providing large margins ( 546-fold) to the projected median unbound Cmax 
at the supratherapeutic dose of 80mg in humans (0. 15μM). In an anesthetized guinea pig 
study, MK -8189 had no effects on HR and ECG parameters. Average peak plasma 
concentrations of MK 8189 measured during the 20 min infusions of 10, 30 and 60 mg/kg 
were 56, 150 and 236 μM, respectively. Thus, the NOEL/NOAEL in this study was 236 μM, 
providing an exposure margin of ~63- fold relative to the projected clinical C maxat the [ADDRESS_952623] on CV parameters 
during rising IV doses up to a 27 μM plasma concentration (~7- fold above the projected 
clinical C maxat 80 mg of 3.75 μM).
08D4MT
PRODUCT: MK-8189  48
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
In a telemetry study in monkeys, single oral doses of 2, 5, and 20 mg/kg were evaluated and 
test article -related dose -independent increases in HR, blood pressu re (BP) and the rate -
corrected QT interval were observed. In a second study at lower oral doses of 0.03, 0.1 and 
0.3 mg/kg, there were no test article -related effects. Thus, the no -observed effect level was a 
single oral dose of 0.3 mg/kg (projected Cmax value of ~0.16 μM, estimated from a 6- week 
toxicity study [<1- fold of the projected clinical Cmax at 80mg of 3.75 μM]). A number of 
studies were conducted to determine the underlying cause (see MK 8189 IB for additional 
details). The general conclusion fr om these studies was that increases in HR, BP and QT 
interval likely occur due to a stress induced release of epi[INVESTIGATOR_701716]10A 
target engagement in conscious rhesus monkeys and therefore, these changes in QT, HR and 
BP are not relevant to h umans. 
Furthermore, a concentration- QTc analysis was conducted in P007 and as shown in Figure 4
there is no evidence for a relationship between concentration and QTc at MK 8189 exposures 
achieved with the 48 mg dose.  Therefore, preclinical and clinical data support dose 
escalation to 80mg in the current study.  In addition, during the study safety and tolerability 
will be carefully assessed.  Dose escalation may be sto pped within an individual or the study 
based on tolerability.
Figure 4Predicted Mean ΔΔQTcF Versus the Observed Geometric Mean Cmax for Each 
Dose Level Along With 90% Confidence Band
08D4MT
PRODUCT: MK-8189  49
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952624] been conducted as a within participant 
titration.   The within participant titration was introduced b ased on results from the single -
ascending dose trial (P001) in healthy participants, where following treatment with the 3- mg 
and 6 -mg IR formulation ,dystonia was observed around the time of peak MK- 8189 
concentration (See IB for details) . One hypothesis for the observed acute dystonia is that the 
high MK -8189 IRformulation peak to trough ratio led to rapid- cycling of MK -8189 on and 
off the target enzyme, PDE10A. In addition to successfully reducing the peak -to-trough ratio 
through development of the CR formulatio n (4 with the IR vs 1.3 with the CR), a titration 
approach in the target patient population was implemented in the multiple ascending dose 
studies (P003 and P007) and the POC (P005) study, which significantly reduced the rate of 
observed EPS and dystonia a nd permitted evaluation of doses and exposures significantly 
greater than could be achieved tolerably with the IR formulation . Of note, in P007, where the 
highest likely clinical dose of [ADDRESS_952625] been 
evaluat ed, no MK -8189 - related dystonia has been reported in healthy participants or 
participants with schizophrenia . The peak concentration values at the 24- mg dose are ~1.7-
fold those observed following 6 mg of the IR formulation, suggesting the absolute 
concen tration is not a driver of dystonia. Across P003 and P007 the starting dose of the CR 
formulation has increased from 2 mg to 4 mg to 8 mg without an increase in the incidence in 
dystonia . Furthermore, Part 1 of P011 was conducted to evaluate the need for t itration in 
participants with schizophrenia. As described in section 2.2.3 (preliminary and blinded data) , 
initiating dosing at 24 mg/placebo was generally well tolerated in participants with 
schizophrenia.  In this panel of participants ,no AEs of EPS wer e reported. 
As this study continue sto explore safety and tolerability of suprat herapeutic doses to support 
the evaluation of concentration -QT effect, a titration approach will be implemented, though it 
will be more aggressive than earlier studies . 
In Panel A and Panel A -1 in participants with schizophrenia, participants will initiate dosing 
at MK -8189 48 mg mg/placebo (Day 1) and escalate to MK-8189 60 mg/placebo in Panel A 
(Day 2) and 80 mg in Panel A -1 (Day 2) .If generally well tolerated, one of the se regimens
would allow for rapid attainment of the necessary exposures to satisfy a TQT study and 
minimize MK-8189 exposure and shorten the duration of the TQT study . Additionally, if 
well tolerated , Panel C will be conducted to support a n integrated (non- clinical and clinical)
concentration- QT analysis per ICH E14 & S7B Q&A [European Medicines Agency 2022]
where doses will be escalated to MK -8189 80 mg/Placebo to potentially negate the need for a 
TQT study.
This study should define the highest tolerated dose that may be explored in a TQT study.
4.[ADDRESS_952626] participant (or their legally acceptable representative) 
provides documented informed consent . The overall study ends when the last participant 
08D4MT
PRODUCT: MK-8189  50
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952627] to follow -up (ie, the 
participant is unable to be contact[CONTACT_19379]) .
For purposes of analysis and reporting, the ove rall study ends when the Sponsor receives the 
last laboratory result or at the time of final contact [CONTACT_26355], whichever comes 
last.
If the study includes countries in the European Economic Area (EEA), the local start of the 
study in the EEA is defined as First Site Ready (FSR) in any Member State.
Astudy may be paused during review of newly available preclinical/ clinical safety, PK , 
pharmacodynamic, efficacy, or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may be necessary to keep the study 
open for gathering/reviewing of additional supportive data to optimally c omplete the 
objective(s) of the study. If necessary, the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the 
study following this review period, the study end will be defi ned as the date of the Sponsor 
decision, and this end of study date supersedes the definitions outlined above . The 
Competent Authority(ies) and IRB(s)/IEC(s) will be apprised of the maximum duration of 
the study beyond the last participant out and the just ification for keepi[INVESTIGATOR_88635].
4.4.[ADDRESS_952628] for Clinical Trials (Appendix 1.1), our studies include 
people of varying age, race, ethnicity, and sex. The collection and use of these demographic 
data are to follow all local laws and guidelines in keepi[INVESTIGATOR_100889], its r elated factors, and the IMP 
under investigation. Prospective approval of protocol deviations to recruitment and 
enrollment criteria, also known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study if the participant meets all of the 
following criteria :
Type of Participant and Disease Characteristics
1. Is in good health based on medical history, physical examination, VS measurements, 
and ECGs performed at the screening visit and/or prior to randomization.  The 
assessment prior to randomization is based on the mean of triplicate measures.  Note:  
TheQTcF -duration must be ≤450 msec, the QRS duration <120 msec and the PR 
interval <[ADDRESS_952629]: MK-8189  51
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952630] a normal resting blood pressure (systolic blood pressure is ≥90 mm Hg and ≤140 
mmHg; diastolic blood pressure is ≥60 mmHg and ≤90 mmHg) and normal resting 
heart rate ( ≥45 beats per minute [bpm] and ≤100 bpm) in the supi[INVESTIGATOR_123626] -
trial (screening) visit and/or prior to randomization. Repeat evaluations may be done if 
the values for a participant are, per investigator discretion, minimally outside the 
designated range. The assessment prior to randomization is based on the mean of the 
triplicate measures. Participants may be included if values are outside the normal range 
but considered not clinically significant per investigator discretion.
3. Is in good health based on laboratory safety tests obtained at the screening visit. 
Appendix [ADDRESS_952631] a Body Mass Index (BMI) > 18.5 and ≤ 40 kg/m2, inclusive, and total body 
weight of > 50 kg (110 lbs) at the screening visit . See Section 8.3.[ADDRESS_952632] whole number. BMI = weight (kg)/height (m)2.
5. Participants with hypothyroidism, diabetes, high blood pressure, chronic respi[INVESTIGATOR_100890] 3 months prior to screening and there are no 
expected changes in co- medication during the study. 
6. Has regular bowel movements and, in the opi[INVESTIGATOR_871], no clinically 
significant diarrhea or consti pation.
7. Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM -5) criteria with the onset 
of the first epi[INVESTIGATOR_123625] 2 years prior to screening and mo notherapy with 
antipsychotics for treatment should be indicated.
8. Has a total Brief Psychiatric Rating Scale (BPRS) score of < 48 with a BPRS score < 4 
for #10 (hostility) and #14 (uncooperativeness) at the screening visit. 
9. Is in the non -acute phase of the ir illness and clinically stable for 3 months prior to 
screening as demonstrated by:
a.no clinically significant change in dose of prescribed antipsychotic medication, or 
clinically significant change in antipsychotic medication to treat symptoms of 
schiz ophrenia for two months prior to screening;
b.no increase in level of psychiatric care due to worsening of symptoms of 
schizophrenia for three months prior to screening.
Note: participants that are stable but not currently taking antipsychotic medications are 
eligible.
08D4MT
PRODUCT: MK-8189  52
PROTOCOL/AMENDMENT NO.: 014-[ADDRESS_952633] 5 days 
or 3 half- lives (whichever is longer) prior to Day -1 and during the study period
Demographics
12. Ismale or female , from 18years to 55years of age inclusive, at the time of providing
informed consent. An attempt will be made to enroll a pproximately 40% of f emale 
participants .
Female Participants
13. A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies: 
•Not a WOCBP
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercour se as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as described in Appendix [ADDRESS_952634] dose of study intervention. The investigator should 
evaluate the po tential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_93300] e participating in clinical studies
-Has a negative highly sensitive pregnancy test (urine or serum as required by [CONTACT_13125]) within [ADDRESS_952635] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.
-Additional requirements for pregnancy testing during and after study intervention are 
inSection 8.3.[ADDRESS_952636]: MK-8189  53
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Informed Consent
14. The participant has provided documented informed consent for the study. The 
participant may also provide consent for future biomedical research ( FBR ). However, 
the participant may participate in the study without participating in FBR .
Additional Categories
15. Willing to comply with the study restrictions (see Section 5.3 for a complete summary 
of study restrictions).
5.[ADDRESS_952637] be excluded from the study if the participant meets any of the following 
criteria :
Medical Cond itions
1. Has an untreated or uncompensated clinically significant renal, endocrine, hepatic, 
respi[INVESTIGATOR_696], gastrointestinal, psychiatric, neurologic, cardiovascular, hematological, 
immunological or cerebrovascular disease, malignance, allergic disease or othe r chronic 
and/or degenerative process at screening.
2. Has any clinically significant abnormal laboratory, VS, physical examination, or 12-
lead safety ECG findings at screening or changes from baseline that may interfere with 
the interpretation of PK or safet y parameters or, in the opi[INVESTIGATOR_871], 
would make the participant inappropriate for entry into this study.
3. Is at imminent risk of self -harm, based on clinical interview and responses on the 
C-SSRS, or of harm to others in the opi[INVESTIGATOR_871].  Participants must be 
excluded if they report suicidal ideation with intent, with or without a plan or method 
(eg, positive response to item 4 or 5 in assessment of suicidal ideation on the C -SSRS) 
in the past [ADDRESS_952638] will be 
required. 
5. Has a history of cancer (malignancy).
Exceptions: (1) Participants with adequately treated nonmelanomatous skin carcinoma 
or carcinoma in situ of the cervix may participate in the study; (2) Participants with 
other malignancies which have been successfully treated ≥10 years prior to the prestudy 
(screening) visit where, in the judgment of both the investigator and treating physician, 
appropriate follow -up has revealed no evidence of recurrence from the time of 
treatment t hrough the time of the prestudy (screening) visit (except those cancers 
identified at the beginning of this exclusion criteria); or (3) Participants, who, in the 
08D4MT
PRODUCT: MK-8189  54
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
opi[INVESTIGATOR_103160], are highly unlikely to sustain a recurrence for the 
duratio n of the study
6. Has evidence or history of a primary DSM -5 axis I psychiatric diagnosis other than 
schizophrenia or schizoaffective disorder per the allowed DSM -5 criteria within one 
month of screening.
7. Has evidence or history of mental retardation, borderline personality disorder, or 
organic brain syndrome.
8. Has a history of neuroleptic malignant syndrome or moderate to severe tardive 
dyskinesia.
9. Has a substance -induced psychotic disorder or behavioral disturbance thought to be due 
to substance abuse. 
10. Has a DSM- 5 defined substance use disorder (excluding nicotine and caffeine) within [ADDRESS_952639] degree AV block, myocardial infarcti on, pulmonary congestion, cardiac 
arrhythmia, prolonged QTc interval, or conduction abnormalities.
13. The participant meets any of the following cardiac parameters: a history of risk factors 
for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT 
syndrome), uncorrected hypokalemia or hypomagnesemia, or is taking concomitant 
medications that prolong the QT/QTc interval. Abnormal serum calcium at Screening 
or prior to dosing.
14. Has history of repeated or frequent syncope, vasovagal e pi[INVESTIGATOR_1841], or epi[INVESTIGATOR_122174].
15. Has a family history of cardiac sudden death
16. Has a history of any illness that, in the opi[INVESTIGATOR_103160], might 
confound the results of the study or poses an additional risk to the participant by [CONTACT_701724].
17. Has a history of significant multiple and/or severe allergies ( eg, food, drug, latex 
allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic 
allergic reaction) to prescription or non -prescription dr ugs or food.
18. Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.
19. Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 
weeks prior to the prestudy (screening) visit.
08D4MT
PRODUCT: MK-8189  55
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Prior/Concomitant Therapy
20. Has receive d or is currently receiving treatment with clozapi[INVESTIGATOR_050] ( eg,fortreatment of
schizophrenia ) for any length of time. Has received treatment with monoamine oxidase 
inhibitors within 3 months of screening or cariprazine within 2 months of screening.
21. Isunable tobewashed offtheir parenteral depot antipsychotic medication prior to
screening orrequires adose ofaparenteral depot antipsychotic medication during the
study.
22. Is unable to refrain from the use of co -medication that is a moderate or strong inhibitor
or inducer of CYP3A or moderate or strong inducer of CYP2C9 beginning 
approximately 2 weeks or 5 half-lives, whichever is longer, prior to administration of 
the initial dose of trial drug and throughout the trial. ( see Section 6.5 ).
23. Has received any nonli ve vaccine starting from 14 days prior to study intervention or is 
scheduled to receive any nonlive vaccine through 30 days following study intervention. 
Exception: COVID -[ADDRESS_952640] 48 hours prior to any COVID- 19 vaccination.   
Investigational COVID -19 vaccines (i.e., those not licensed or approved for Emergency 
Use) are not allowed.
Prior/Concurrent Clinical Study Experience
24. Participated in another investigational study within 4 weeks (or 5 half-lives, whichever 
is greater) prior to the prestudy (screening) visit. The window will be derived from the 
date of the last visit in the previous study.
Diagnostic Assessments
Not applicable.
Other Exclusions
25. Under the age of legal consent.
26. Is a smoker that does not agree to follow the smoking restrictions as defined by [CONTACT_47391].
27. Consumes greater than 3 servings of alcoholic beverages (1 serving is approximately 
equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] 
[29.5 mL/1 ounce]) per day. Participants who consume 4 servings of alcoholic 
beverages per day may be enrolled at the discretion of the investigator.
28. Consumes excessive amounts, defined as greater than 6 servin gs (1 serving is 
approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day.
08D4MT
PRODUCT: MK-8189  56
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
29. Is a regular user of cannabis, any illicit drugs or has a history of drug (including 
alcohol) abuse within approxi mately [ADDRESS_952641] a negative UDS 
(with the exception of cannabis and/or prescribed concomitant medications permitted at 
the discretion of the PI [INVESTIGATOR_80336]) prior to randomization.
30. The investigator has a ny concern regarding safe parti cipation in the study or for any 
other reason the investigator considers the participant inappropriate for participation in 
the study.
31. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site o r Sponsor staff directly involved with this study.
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
[IP_ADDRESS] Diet Restrictions
Fasting requirements for study procedures, such as but not limited to laboratory safety 
evaluations are specified in Appendix [ADDRESS_952642] dose .
Meals and snack(s) will be provided by [CONTACT_701725]. 
Participants will fast from all food and drinks, except water ,between meals and snacks. For 
multicenter studies the meal c ontent should be consistent within a given clinical site. Meals 
and snacks will be served after any coinciding Holter and/or PK procedure.   
The caloric content and composition of meals will be the same . Afterthe [ADDRESS_952643] been comp leted in Panels A andA-1, subsequent meals and snacks will be 
unrestricted in caloric content, composition and timing.
Water will be provided during study intervention administration. Water will be restricted 
1hour before and 1 hour after study intervent ion administration.
Meal and water restrictions on Day - 1 will be time -matched to those timepoints on 24- hour 
Holter/PK days when treatment is administered.  Similarly, during intermediate days and the 
days following the last scheduled dose , meal and water restrictions will be time -matched to 
24-hour Holter/PK days when treatment is administered.
Each study intervention administration will need to be taken with water. Water will be 
restricted [ADDRESS_952644]: MK-8189  57
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
[IP_ADDRESS] Fruit Juice Restrictions
Participants will refrain from the consumption of grapefruit juice, grapefruits, and grapefruit 
products beginning approximately 2 weeks before administration of the initial dose of study 
intervention, throughout the study and until the poststudy visit.
On full PK sampling days (ie, Panels A and A -1Days 1-2, Panel C Days 1-3 ),participants 
will refrain from the consumption of all fruit juices 24 hours before study intervention
administration and during the entire day.
Onall other days during the study, the consumption of all fruits and fruit juices (except for 
grapefruit, grapefruit juices, and grapefruit products) is allowed .
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours before the prestudy and poststudy visits. On full PK sampling days 
(ie, Panel A and A -1Days 1-2) and 24 -hour Holter monitoring days (ie, Panel C Days 1 -3),
participants will be permitted to consume approximately [ADDRESS_952645] dose. Otherwise, 
participants will refrain from consumption of such products 8 hours prior to study drug 
administration until the 24- hour postdose ECG/PK assessment is complete.
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours before the pr estudy and 
poststudy visits. During the in- house period, consumption of alcohol is not allowed. Atall 
other times, alcohol consumption is limited to no more than approximately 3 alcoholic 
beverages or equivalent servings (1 serving is approximately equiva lent to: beer 
[354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL/1 ounce]) per day.
[IP_ADDRESS] Tobacco Restrictions
Smoking restrictions (and if applicable, the use of nicotine/nicotine -containing products) 
defined by [CONTACT_701726].
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous physical activity (ie, weightlifting, running, 
bicycling, etc) from the prestudy (screening) visit until administration of the initial dose of 
study intervention, throug hout the study (including washout intervals between treatment 
periods) and until the poststudy visit.
08D4MT
PRODUCT: MK-8189  58
PROTOCOL/AMENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently entered in the study. A minimal set of screen- failure information may be 
included, as outlined in the eCRF entry guidelines. Minimal information may include 
demography, screen -failure details, eligibility criteria, and any AEs or SAEs meeting 
reporting requirements.
5.5 Part icipant Replacement Strategy
If a participant discontinues from study intervention OR withdraws from the study a 
replacement participant may be enrolled if deemed appropriate by [CONTACT_50093]. The replacement participant will generally recei ve the same intervention or 
intervention sequence (as appropriate) as the participant being replaced. The replacement 
participant will be assigned a unique treatment/randomization number.
The replacement participant may begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a stud y participant according to 
the study protoco l.
Clinical supplie s [study intervention(s) provided by [CONTACT_1034]] will be packaged to support 
enrollment and replacement participants as required. When a replacement participant is 
required, the Sponsor or des ignee needs to be contact[CONTACT_88675] . Clinical supplies will be affixed with a clinical label in accordance with 
regulatory requirement s.
6.1 Study Intervention(s) Administered
The study intervention to be used in this study isoutlined inTable [ADDRESS_952646]: MK-8189  59
PROTOCOL/AM ENDMENT NO.: 014-05
MK-8189 -014-05 FINAL PROTOCOL 18-NOV -2022
Table 1 Study Intervention s
Arm 
Name [CONTACT_151579] -
vention 
NameInter -
vention 
TypeDose
FormulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationTreatment
Regimen UseIMP or
NIMP /
AxMP Sourcing
Panel A 
ActiveExperimental MK-[ADDRESS_952647] 
ProductIMP Provided 
centrally
Placebo Placebo 
ComparatorMK-8189 Drug Tablet 0 mg All 
dosage 
levelsOral All Panels Placebo IMP Provided 
centrally
IMP=investigational medicinal product; NIMP/AxMP=noninvestigational/auxiliary medicinal product.
The classification of IMP and NIMP/AxMP in this table is based on guidance issued by [CONTACT_301793] 
(EEA). Country differences with respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstanc es, local legislation is followed.
08D4MT
PRODUCT:   MK-8189  60
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
All supplies indicated in Table 1 will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/batch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.[ADDRESS_952648].
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_952649] be store d 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medic al institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring tha t a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
08D4MT
PRODUCT:   MK-8189  61
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants will be assigned randomly according to a computer -generated allocation 
schedule.
The sample allocation schedules areprovided in Table 2(Panel A), Table 3 (Panel A-1 ), 
Table 4 (Panel C).
Table 2 Panel A Schizophrenic Sample Allocation Schedule
naDay 
1Day 
2
9 48mg 60mg
3 PBO PBO
aAn attempt will be made to enroll a pproximately 40% female participants
Note: The allocation scheduled will be stratified to females and males. 
Female participants will be assigned the low allocation range and male 
participants will be assigned the upper allocation range.
Table 3 Panel A-1 Schizophrenic Sample Allocation Schedule
naDay 
1Day 
2
9 48mg 80mg
3 PBO PBO
aAn attempt will be made to enroll approximately 40% female participants
Note: The allocation scheduled will be stratified to females and males. 
Female participants will be assigned the low allocation range and male 
participants will be assigned the upper allocation range.
Table 4 Panel C Schizophrenic Sample Allocation Schedule
naDay 
1Day 
2Day
3
1848mg 48mg 80mg
12 PBO PBO PBO
aAn attempt will be made to enroll a pproximately 40% female participants
Note: The allocation scheduled will be stratified to females and males. 
Female participants will be assigned the low allocation range and male 
participants will be assigned the upper allocation range.
08D4MT
PRODUCT:   MK-8189  62
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
6.3.2 Stratification
The allocation schedule swill be stratified to females and males. Female participants will be 
assigned the low allocation range and male participants will be assigned the upper allocation 
range to attempt to ensure approximately 40% of females .
6.3.3 Blinding
A double -blinding technique will be used.  MK -8189 and placebo will be prepared and/or 
dispensed in a blinded fa shion by [CONTACT_701727]. 
The participant and the investigator who is involved in the study intervention administration 
or clinical evaluation of the participants are unaware of the group assignments .
See Section 8 .1.10 for a description of the method of unblinding a participant during the 
study should such action be warranted.
6.4 Study Intervention Compliance
Interruptions from the protocol -specified treatment plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second member of the study- sitestaff.
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and rec orded in the CRF. 
The dose of study intervention and study participant identification will be confirmed at the 
time of dosing by a member of the study- sitestaff other than the person administering the 
study intervention. Study -site personnel will examine each participant’s mouth to ensure that 
the study intervention was ingested.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during the ongoing study . If there is a clinical indication for any medications or vaccinations
specifically prohibited, discontinuation from study intervention may be required. The 
investigator should discuss any questions regarding this with the Sponsor Clinical Director . 
The f inal decision on any supportive therapy or vaccination rests with the investigator and/or 
the participant’ s primary physician. However, the decision to continue the participant on 
study intervention requires the mutual agreement of the investigator, the Sp onsor, and the 
participant.
08D4MT
PRODUCT:   MK-8189  63
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements )that the participant is receiving at the time of enrollment or 
receives during the study must be recorded al ong with:
•Reason for use
•Dates of administration including start and end dates
•Dosage information including dose and frequency
Paracetamol/acetaminophen (up to 4 g per day) and ibuprofen (up to 1.2g per day) and 
antacids ( eg,magnesium hydroxide) may be used for minor ailments without prior 
consultation with the Sponsor.
For participants with schizophrenia, medications to treat mild chronic conditions such as 
hypothyroidism, diabetes, high blood pressure, chronic respi[INVESTIGATOR_701717] -medication during the study.  Moderate to strong inhibitors or induce rs of 
CYP3A and moderate or strong inducers of CYP2C9 are not allowed.  
In addition, the following concomitant medications/vaccinations are permitted:
•Nonlive vaccines may only be administered in consultation with the Sponsor prior to or 
following the r eceipt of study intervention according to the time frames specified in 
Exclusion Criteria (Section 5.2).
Exception: COVID -[ADDRESS_952650] 48 hours prior to any COVID -19 vaccination.
Investigational COVID -19 vaccines (i.e., those not licensed or approved for Emergency Use) 
are not allowed. The Sponsor Clinical Director should be contact[CONTACT_51013].
6.5.1 Rescue Medications and Supportive Care
For the treatment of EPS, such as acute dystonia, all participants may be treated with an 
anticholinergic. If the symptoms are unresponsive to anticholinergic treatment or not 
recommended based on a participant’s medical history/conc omitant medication , a 
benzodiazepi[INVESTIGATOR_528896].
In case the participant presents with signs of akathisia without signs of dystonia, the 
participant can be treated with a β -adrenergic blocker. If symptoms do not disappear with the 
β-adrenergic blocker, tr eatment with an anticholinergic may be used.  An anticholinergic may 
be used as first -line treatment in the case that a β -adrenergic blocker is not a preferred 
treatment based on a participant’s medical history and/or concomitant medication.
08D4MT
PRODUCT:   MK-8189  64
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952651] 3 half -lives of the drug 
(whichever is longer) prior to Day -1 assessments (this includes any rescue me dication given 
during the washout period).  During the washout and treatment period, a benzodiazepi[INVESTIGATOR_701718]. The drugs indicated above should not 
bemoderate or strong inhibitors or inducers of CYP3A or moder ate or strong inducers of 
CYP2C9 (see Section 6.5 for further details), thus no effect on the PK of MK -8189 would be 
expected during co -administration.
6.6 Dose Modification (Escalation/Titration/Other)
If, as judged by [CONTACT_1052] /orinvestigator, the safety and tolerability data do not justify 
dose titration, the dose will not be increased as planned. Instead, participants may:
•Skip a single dose and dosing may continue at the same dose level or adjusted 
downwards 
•Receive the same dose level to further explore safety and tolerability at that level
•Receive a lower dose of the study intervention
•Dosing may be stopped 
If app ropriate medical care necessitates dosing to be stopped or a lower dose given, the 
investigator may do so without consultation with the Sponsor.
Participant discontinuation criteria are outlined in Section 7.
6.7 Intervention After the End of the Study
There i s no study- specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention allocation/randomization 
schedule for the study to unblind participants and to unmask study interventi onidentity. The 
emergency unblinding call center should only be used in cases of emergency (see Section 
8.1.10). The Sponsor will not provide random code/disclosure envelopes or lists with the 
clinical supplies.
This study is blinded, but supplies are pro vided open label; therefore, an unblinded 
pharmacist or qualified study- site personnel will be used to blind supplies. Study intervention 
identity (name, strength, or potency) is included in the label text.
08D4MT
PRODUCT:   MK-8189  65
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952652] be collected through the participant’s last scheduled follow -up, even if 
the participant has discontinued study intervention. Therefore, all participants who 
discontinue study intervention before completion of the protocol -specified treatment 
period/vaccination regimen will still continue to participate in the study as specified in
Section 1.[ADDRESS_952653] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_296465], the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.9.
A participant must be discontinued from study intervention, but continue to be monitored in 
the study, for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study intervention.
•The participant’s treatment assignment has been unblinded by [CONTACT_093], MSD 
subsidiary, or through the emergency unblinding call center.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•Participants with severe EPS symptoms will be discontinued if not attenuated with dose 
reduction, titration, or medical management.
•The participant has a confirmed positive serum pregnancy test.
•The participant has a positive UDS at any time during the course of the study. The drug 
screen can be confirmed by a recheck at the discretion of the investigator after discussion 
with the Sponsor.
Discontinuation from study intervention is“permanent.” Once a participant is discontinued
from study intervention, they shall not be allowed to restart study intervention .
08D4MT
PRODUCT:   MK-8189  66
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952654] be withdrawn from the study if the participant or participant’s lega lly 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from FBR ,are outlined in Section 
8.1.9. The procedures to be performed should a participant repeatedly fail to return for 
scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
7.[ADDRESS_952655] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or de signee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_660215]’s medical record.
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines.
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study- site personnel responsibilities will be docu mented in the Investigator Trial File 
Binder ( or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
08D4MT
PRODUCT:   MK-8189  67
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigato r will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count ) and obtained before signing of ICF may be u sed for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
•Additional evaluations/testing may be deemed necessa ry by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may require that additional informed conse nt be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 225mL(Appendix 8).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative ) prior to participating in thisclinical study or FBR . If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
[IP_ADDRESS] General Informed Consent
Informed c onsent given by [CONTACT_19429] a consent form . The form must include the study protocol number, study 
protocol title, dated signature , and agreement of the participant ( orhis/her leg ally acceptable 
representative ) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB /IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue p articipation in the study. The communication of this information will be provided 
08D4MT
PRODUCT:   MK-8189  68
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s da ted 
signature.
If the investigator recommends continuation of study intervention beyond disease 
progression, t he participant or their legally acceptable representative will be asked to provide 
documented informed consent.
Specifics about the study and the study population are to be included in thestudy informed
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performin g any procedure re lated 
to FBR. A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR .
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physici an,to ensure that the participant qualifies for the study.
8.1.[ADDRESS_952656] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention allocation,
site personnel will add the treatment /randomization number to the participant identification 
card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.[ADDRESS_952657]:   MK-8189  69
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol -specified washout requirement, and record prior medication taken by [CONTACT_88688] [ADDRESS_952658] be discussed between the investigator and Sponsor, 
unless appropriate medical care necessitates that therapy or vaccination should begin before 
the investigator and Sponsor can consult.  Note: medications permitted under Section 6.5 of 
the protocol do not need to be discussed prior to use.
Washout from Antipsyc hotics :
All participants will be washed out from their antipsychotic medication prior to Day -[ADDRESS_952659] not be reused for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial Screening V isit. Specific details on the screening/rescreening visit 
requirements are in Section 8.10.1.
8.1.7 Assignment of Treatment/ Randomization Numb er
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment /randomization number is assigned to a participant, it can never be reassigned to 
another participant.
A single particip ant cannot be assigned more than 1 treatment /randomization number.
08D4MT
PRODUCT:   MK-8189  70
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
8.1.8 Study Intervention Administrati on
Study intervention(s) will be administered by [CONTACT_1755]/or study staff. Participants 
will fast from all food and drinks, except water, for at le ast [ADDRESS_952660] swallowed study treatment .
[IP_ADDRESS] Timing of Dose Administration
Participants will be dosed according to the SoA (Section 1.3). MK-8189 Treatment 
administration will be in the AM at approximately the same time each day (within a 30 
minute window) and will occur after an [ADDRESS_952661] 
scheduled meal .Participants will receive each oral dose of MK -8189/placebo with ~240mL 
of water .
8.1.[ADDRESS_952662] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study and/or intervention. If a participant discontinues for 
any reason at any time during the course of the study and/or intervention, the participant may 
be asked to return to the clinic (or be contact[INVESTIGATOR_530]) for a poststudy visit as per the number of 
days described in Section 8.11.[ADDRESS_952663] the applicable procedures conducted. However, the 
investigator may decide to perform th e poststudy procedures at the time of discontinuation or 
as soon as possible after discontinuation. If the poststudy visit occurs prior to the safety 
follow -up time frame as specified in Section 8.4.1, the investigator should perform a follow -
up telephone call at the end of the follow -up period (Section 8.4.1) to confirm if any AEs 
have occurred since the poststudy clinic visit. Any AEs that are present at the time of 
discontinuation/withdrawal should be followed in accordance with the safety requirements 
outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for FBR . Participants may withdraw consent at any 
time by [CONTACT_701728]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
(clinical.specimen.management@ MSD .com). Subsequently, the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdr awal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any analyses in progress at the time of request for withdrawal or 
already performed before the request being received by [CONTACT_88691]. No new analyses would be generated 
after the request is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a link between the participant’s personal 
08D4MT
PRODUCT:   MK-8189  71
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952664] for specimen withdrawal 
cannot be processed .
8.1.10 Participant Blinding/Unblindi ng
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the invest igator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/ she will contact [CONTACT_88693] a request fo r emergency unblinding. As requested by [CONTACT_19445] , the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is qualified physician should make reasonable attempts to enter the
intensityof the AEs observed, th e relation to study intervention, the reason thereof, et c, in the 
medical record . If it is not possible to record this assessment in the medical record before the 
unblinding, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified as soon as possible.
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the approp riate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_941] i nvestigator or medically 
qualified designee and/or non study treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
8.1.11 Domiciling
Participants in Panel A and Panel A-1will be domiciled in the study unit minimally from 
Day -1 until Day 5 procedures are complete. Participants in Panel Cwill be domiciled in the
study unit minimally from Day -2until Day 6 procedures are complete .
For any participant who is required to wash off antipsychotic therapy, domiciling will begin 
on Day -6.At the discretion of the investigator, participants may be requested to remain i n 
the CRU longer.
8.1.12 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
08D4MT
PRODUCT:   MK-8189  72
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study si te.
8.[ADDRESS_952665] efficacy assessments in this study; surrogate markers of efficacy are 
outlined in Section 8.7.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. The total amount of blood/tissue to be drawn/collected over the course of the study 
(from prestudy to poststudy visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_113802], can be found in Appen dix 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
Complete physical examinations will be conducted by [CONTACT_88696] (consistent with local requirements) per institutional standard. at prespecified 
timepoints noted in the SoA (Section 1.3). Height and weight will also be measured and 
recorded.
Brief directed physical examinations will be conducted by [CONTACT_113803] (consistent with local requ irements) per institutional standard at 
prespecified timepoints noted in the SoA (Section 1.3).
BMI
BMI equals a person's weight in kilograms divided by [CONTACT_55739] 
(BMI=kg/m2). BMIwill be rounded to the nearest whole number according to the standard 
convention of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
•Body temperature, heart rate , respi[INVESTIGATOR_697] , and blood pressure will be assessed at 
prespecified timepoints noted in the SoA (Section 1.3). 
•BP and heart rate measurements will be assessed in a supi[INVESTIGATOR_103645] a completely 
automated device. Manual techniques will be used only if an automated device is not 
available.
08D4MT
PRODUCT:   MK-8189  73
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
[IP_ADDRESS] Resting Vital Signs
Vital Sign Measurements (Heart Rate and Blood Pressure)
Participants should be resting in a quiet setting without distractions in a supi[INVESTIGATOR_42428] [ADDRESS_952666] positioning on the participants' arm is essential t o 
increase the accuracy of BP measurements.
The predose (baseline) HR and BP will be triplicate measurements, obtained at least [ADDRESS_952667] dose equivalent timepoint on Day -1.The mean of these 
measurements will be used as the baseline to calculate change from baseline for safety 
evaluations (and for rechecks, if needed). Postdose VS measurements will be single 
measurements.
Body Temperature
Body temperature will be measured. T he same method must be used for all measurements for 
each individual participant and should be the same for all participants within a given clinical 
site
[IP_ADDRESS] Orthostatic Vital Signs
During Panels A-1 and C , orthostatic VS (HR and systolic and diastolic BP) wil l also be 
obtained following resting HR and BP measurements . Participants should be supi[INVESTIGATOR_290601] 10 minutes and thenstand upright for 2 minutes prior to measurement of orthostatic VS.
8.3.3 Electrocardiograms
Triplicate 12- lead ECG on Day - 1 will be obtained and reviewed by [CONTACT_306171] (consistent with local requirements) as outlined in the SoA 
using an ECG machine that automatically calculates the HR and measures PR, QRS, QT, and 
[QTc] intervals. Refer to Inclusion/Exclusion criteria and Appendix 9foreligibility 
assessment and potentially significant findings.
Special care must be taken for proper lead placement by [CONTACT_5944]. Skin should be 
clean and dry before lead placement. Participants may ne ed to be shaved to ensure proper 
lead placement. Female participants may need to remove interfering garments.
Participants should be resting in the supi[INVESTIGATOR_1919] [ADDRESS_952668]:   MK-8189  74
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
electrodes, 12 -lead electrode sites will be marked on the s kin of each participant with an 
ECG skin- marker pen to ensure reproducible electrode placement .
Predose ECGs will be obtained per the schedule of activities on Day -1. These measurements 
will be used as the baseline to calculate change from baseline for sa fety evaluations (and for 
rechecks, if needed).
During each treatment period, if a participant demonstrates an increase in QTc interval 
≥60msec compared with mean predose baseline measurement, the ECG will be repeated 
twice within 5 minutes. The mean valu e of the QTc interval from the 3 ECGs will represent 
the value at that time point. If the mean QTc interval increase from baseline (Day -1)for any 
postdose time point is ≥[ADDRESS_952669] 1 hour or until the QTc is within 60 msec of 
baseline. If prolongation of the QTc interval ≥[ADDRESS_952670] may be appropriate and the Sponsor should be notified.
During each treatment peri od, if a participant demonstrates a QTc interval ≥500msec on a 
postdose ECG , the ECG will be repeated twice within 5 minutes. The mean value of the QTc 
interval from the 3 ECGs will represent the value at that time point. If the mean QTc interval 
is ≥[ADDRESS_952671]. T he participant should be telemetry monitored ( until the QTc is <500 msec ) or 
should be considered for transfer to a location where closer monitoring and definitive care 
(eg, a CCU or ICU) is available.
If at any time the QRS duration is prolonged ≥200 msec (and change is not considered rate 
related or pacing induced), then the Sponsor should be notified. The ECGs should be 
reviewed by a cardiologist and the participant should be considered for transfer to a location 
where closer monitoring and definitive care (eg, a CCU or ICU) is available.
If the participant has unstable hemodynamics, or has any clinically significant dysrhythmias 
noted on telemetry, the participant should be immediately transferred to an acute care setting 
for definitive therapy.
If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and t he QTc is <[ADDRESS_952672] will be consulted by [CONTACT_326652].
24-Hour Holter Assessment
For the entire 24- hour Holter recording duration, participants should not wear metal jewelr y 
such as watches, necklaces, and/or bracelets from the waist up. Participants must also not use 
electronic devices such as cell phones, computers/laptops, MP3 players, etc. during Holter 
recording. Holter recording will be turned on approximately 30 minut es prior to trial drug 
administration. Participants will not be allowed to shower/bath for the duration of the [ADDRESS_952673]:   MK-8189  75
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Holter data will be extracted (in triplicate) and analyzed using automated and semi -
automated methods by a blinded co re ECG laboratory according to a pre -specified algorithm. 
To minimize artifacts, participants must rest quietly in a supi[INVESTIGATOR_19636] ~10 minutes
prior to the time points specified for extraction . The extraction window will be 10 minutes. 
No other study assessments or procedures should occur during the resting period. 
Holters may be removed and reapplied (same Holter used by [CONTACT_326654]) per the 
instructions in the Acquisition Guide for Holter -recordings provided by [CONTACT_326655].  
Lead placem ent must be marked anytime electrodes are removed.  
See the Acquisition Guide provided by [CONTACT_326656].
Procedures for transfer, archiving, and review of ECGs will be specified by [CONTACT_326655] .
8.3.[ADDRESS_952674] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, docu ment this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are no t associated with the underlying disease, unless 
judged by [CONTACT_19448] ’s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_952675] be 
conducted in accordance with the la boratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_20616] r (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_952676] dose of study intervention , every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by [CONTACT_093] .
8.3.5 Pregnancy Testing
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
Additional serum or urine pregnancy tests may be performed, as determined necessary by [CONTACT_41011], to establish the absence of pregnancy at any time 
during the subject's participation in the study.
08D4MT
PRODUCT:   MK-8189  76
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
8.3.6 Suicidal Ideation and Behavior Monitoring
[IP_ADDRESS] Clinical Assessments for Suicidal Ideation and Behavior Monitoring
Suicidal ideation and behavior will be prospectively assessed during this study using the C -
SSRS. The C -SSRS should be administere d by [CONTACT_88698] S oA. In addition, C -SSRS will be administered at any unscheduled visit where safety 
assessments are performed. The C -SSRS will not be routinely admini stered at visits with a 
sole purpose of PK sampling and/or witnessed study intervention administration. Site staff 
should review the con tents of the C -SSRS for complete ness. If the C -SSRS is administered 
by [CONTACT_123671], consider providing the completed C -SSRS to the 
investigator for review, before their assessment of the participant and to further inform their 
evaluation. The C -SSRS is not explicit about whether the participant specifically has ideation 
at the time of screening. If a participant reports a prior history of ideation/behavior at 
screening, the assessor should also inquire and document if this is also present at the time of 
the S creening V isit.
[IP_ADDRESS] Monitoring for Extrapyramidal Symptoms
The investigator or qualified designe e will complete the BARS, AIMS and SAS at times 
specified in the SoA. Additional assessments at unscheduled times outside of the SoA will be 
conducted by [CONTACT_464], as soon as reasonably possible, if it is observed or a participant 
reports complaints of dystonia and/or akathisia. 
8.3.7 Assessment of Neuropsychological Effects
Ageneral (full) Neurological Exam will be performed at the Screening visit , Baseline and 
prior to discharge . A targeted Neurological Exam will be administered at times specified in 
the SoA . 
ABPRS evaluation will be performed at Screening, Baseline and will also be completed at 
times specified in the SoA.
The General and Targeted Neurological Exams are contained in Appendix 11.
8.3.[ADDRESS_952677]:   MK-8189  77
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events.
Investigators need to document if an AE and/or SAE was associated with a medication error, 
misuse , or abuse. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
8.4.1 Time Period and Frequency for Collecting AE, SAE ,and Other Reportable 
Safety Event Information
AEs, SAEs, and other reportable safety events that occur after the participant provides 
documented informed consent , but before intervention allocation/randomization, must be 
reported by [CONTACT_123672]:
•if the participant is receiving placebo run -in or other run-in treatment,
•if the event causes the participant to be excluded from the study,
•if it is the result of a protocol -specified intervention, including ,but not limited to washout 
or discontinuation of usual therapy, diet, placebo, or a procedure.
From th e time of intervention allocation/randomization through [ADDRESS_952678]:   MK-8189  78
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received study intervention.
Table 5 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -specified 
Follow -up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Report if:
-drug/vaccine 
related.
(Follow ongoing to 
outcome)Within 24 hours 
of learning of 
event
Pregnancy/
Lactation 
ExposureReport if:
-participant has been 
exposed to any 
protocol -specified 
intervention (eg, 
procedure, washout or 
run-in treatment 
including placebo run -
in)
Exception: A positive 
pregnancy test at the 
time of initial screening 
is not a reportable 
event.Report all Previously reported 
–Follow to 
completion/
termination; report 
outcomeWithin 24 hours 
of learning o f 
event
ECI (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-potential DILI
-require regulatory 
reportingNot required Within [ADDRESS_952679]:   MK-8189  79
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Type of EventReporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -specified 
Follow -up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor:
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar 
days of learning 
of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning 
of event
(unless serious)
Overdose Report if:
-receiving placebo run -
in or other run -in 
medication Report all Not required Within 24 hours 
of learning of 
event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; 
SAE=serious adverse event.
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report , the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized] participan ts for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study intervention under clinical investigation are m et.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requireme nts and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forwarded to investigators as necessary.
08D4MT
PRODUCT:   MK-8189  80
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/IEC, if ap propriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or S AE.
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anomalies that leads to an elec tive termination of a 
pregnancy will be reported as an SAE for the fetus.
Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Disease -related Events and/or Disease -related Outcomes not qualifying as AEs or SAEs are 
not applicable to this study.
8.4.[ADDRESS_952680] for this study include:
1.An overdose of Sponsor's product, as defined in Section 8.5.
2.An elevated AST or ALT laboratory value that is greater than or equal to 3X the ULN 
and an elevated total bilirubin laboratory value that is greater than or equal to 2X the 
ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X 
the ULN, as determined by [CONTACT_13149] -specified laboratory testing or unscheduled 
laboratory testing.*
*Note: These criteria are based on available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology. The study -site guidance for assessment 
08D4MT
PRODUCT:   MK-8189  81
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
and follow up of these criteria can be found in the Investigator Study File Binder (or 
equivalent).
It may also be appropriate to conduct additional evaluation for an underlying etiology in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not meet the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study investigators 
and the Sponsor Clinical Direct or. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study.
3.Severe EPS or EPS leading to study discontinuation
4.Treatment -emergent adverse event of new or worsening tardive dyskinesia
5.Suicidal ideat ion, suicidal behavior 
6.Moderate or severe depression
7.Moderate or severe mood swings
8.Dystonia
8.4.8 Medical Device and Drug- device Combination Products -PQCs/Malfunctions
Not applicable
8.5 Treatment of Overdose
For purposes of this study, an overdose will be defin ed as any dose of any drug administered 
as part of the study exceeding the dose prescribed by [CONTACT_760]. It is up to the investigator 
or the reporting physician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
Sponsor does not recommend specific treatment for an overdose. Decisions regarding dose 
interruptions or modifications will be made by [CONTACT_508231].
8.6 Pharmacokinetics
The decision as to which plasma and/or urine samples collected will be measured for 
evaluation of PK/pharmacodynamics will be collaboratively determined by [CONTACT_1034] (eg, 
samples at lower doses may not be measured if samples at higher doses reveal undetectable 
drug concentrations). If indicated, these samples may also be measured and/or pooled for 
assay in an exploratory manner for metabolites and/or additional pharmacodynamic markers .
8.6.1 Bloo d Collection for Plasma MK -8189
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the O perations/ Laboratory Manual .
08D4MT
PRODUCT:   MK-8189  82
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
8.7 Pharmacodynamics
ECG parameter values are extracted from 24 -hour Holter monitoring per the SoA.
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA:
•Blood for Genetic Analysis
8.8.[ADDRESS_952681] e Collection
The planned genetic a nalysis sample will be drawn for CYP2C9 genotypi[INVESTIGATOR_88645]. If the 
IRB/IEC does not approve of the planned analysis of the association b etween DNA variation 
and drug response, or if there is a local law or regulation prohibiting the same, data analysis 
will be limited to CYP2C9 . Leftover extracted DNA will be stored for FBR if the participant 
provides documented informed consent for FBR .
Sample collection, storage, and shipment instructions for planned genetic a nalysis samples 
will be in the operations/laboratory manual .
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the follow ingspecime ns 
will be obtained as part of FBR :
•Leftover DNA for future research
•Leftover main study plasma from MK -8189 and/or metabolites assay stored for future 
research
8.10 Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedur e-related details areprovided 
inSection 8.
8.10.1 Screening
Within approximately 6 weeks before intervention allocation/randomization, potential 
participants will be evaluated to determine that they fulfill the entry requirements as set forth 
in Section 5.
Participants may be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day prior to intervention allocation/randomization since
there are Day - [ADDRESS_952682]:   MK-8189  83
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952683] 3 half -lives of the drug (whichever is longer) prior to Day -1. Participants will report to 
the CRU on Day - 6 to start their wa shout period. However, if participants are not currently 
being treated with antipsychotic medications and therefore do not require a washout, they 
may be domiciled on Day -2 in Panel C, or Day -1 in Panels A andA-1.
On treatment days participants will be dosed once daily with MK -8189/placebo and have 
procedures completed per the So A. Participants will remain in the unit through [ADDRESS_952684] study clinic visit.
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study, the ECG pa rameter values extracted from the [ADDRESS_952685] time point as 
possible. The PK sample should follow immediately after the Holter extraction window is 
complete .  All other procedures should be completed as close to the prescribed/scheduled 
time as possible. Study procedures can be performed before or after the prescribed/scheduled 
time.
The order of priority can be changed during the study with joint agreement of the investigator 
and the Sponsor Clinical Director.
08D4MT
PRODUCT:   MK-8189  84
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.
1.Holter ECG assessment (extraction period)
2. 12- Lead Safety ECG
3.Resting Blood Pres sure and Heart Rate
4.Blood for MK -8189
5.Neurological exams, C- CSSRS, BPRS , BARS, AIMS, SAS
The following variance in procedure collection times will be permitted.
•PK Collection of samples which are not time -matched to Holter ECG assessments as 
outlined in Table 6 .
Table 6 Pharmacokinetic (Blood) Collection Windows for samples not time -matched to 
Holter ECG assessments
PK Collection PK Collection Window
0 to <1 h 5 min
1 to <24 h 15 min
24to <48 h 1 h
48to 168 h 2 h
˃168 h 24 h
•Predose standard safety evaluations: VS and ECG triplicate measurements on Day - [ADDRESS_952686] -dose equivalent timepoint within 1 hour ;physical exam 
within 24 hours and laboratory safety tests within 48 hours prior to dosing .
•Postdose standard safety evaluations : VS, ECG, laboratory safety tests, andphysical 
exam :
- P rior to 24 -hours postdose may be obtained within 15 minutes of the theoretical 
sampling time
- Between 24- hours and 48- hours postdose may be obtained within 1 hour of the 
theoretical sampling time
-From 48 -hours to 168- hours postdose may be obtained within 2 hours of the 
theoretical sampling time
•Study intervention administration (multiple dose studies only) : at30 min utes.
08D4MT
PRODUCT:   MK-8189  85
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of MK- 8189 in humans, and the PK, pharmacodynamic, and 
safety profiles of the compound arestill being elucidated. This protocol is written with some 
flexibility to accommodate the inherent dynamic nature of Phase 1 clinical studies. 
Modifications to the dose, dosing regimen, and/or clinical or laboratory procedures currently 
outlined may be required to achieve the scientific goals of the study objectives and/or to 
ensure appropriate safety monitoring of the study participants.
As such, some alterations from the curre ntly outlined dose and/or dosing regimen may be 
permitted based on newly available data, but the maximum daily dose may not exceed those 
currently outlined in the protocol.
•Repeat of or decrease in the dose and/or titration steps of the study intervention 
administered panel
•Repeat of a panel at the same dose regimen or more conservative dose regimen.
•Entire period(s) or panel(s) may be omitted
•Decrease in the duration of study intervention administration (eg, number of days)
•Adjustment of the dosing interval (eg, divided doses [ bid to qd, qd to bid , tid, or vice 
versa])
•Addition of PK pause
•Instructions to take study intervention with or without food or drink may also be modified 
based on newly available data
•Modification of the PK/pharmacodynamic sam ple processing and shippi[INVESTIGATOR_508216]/pharmacodynamic sampling scheme currently outlined in the protocol may be 
modified during the study based on newly available PK or pharmacodynamic data (eg, to 
obtain data closer to t he time of peak plasma concentrations). If indicated, these collected 
samples may also be assayed in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
Up to additional 50 mL of blood may be drawn for safety, PK, and/or pharma codynamic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
The timing of procedures for assessment of safety procedures (eg, vital signs, ECG, safety 
laboratory tests, etc) may be modified during the study based on newly available data. 
Additional laboratory safety tests may be added to blood samples previously drawn to obtain 
08D4MT
PRODUCT:   MK-8189  86
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
additional safety information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study.
It is understood that the current study may usesome or none of the alterations described 
above. Any alteration made to this protocol to meet the study objectives must be detailed by 
[CONTACT_21411] a letter to the Study File and forwarded to the investigator for retention. The 
letter may be forwarded to the IRB/IEC at the discretion of the investigator .
9 STATISTICAL ANALYSIS PLAN
This section contains a brief summary of the statistical analyses for this trial. Full detail is in
the Statistical Analysis Plan (SAP) (Section 9.2).
9.1 Statistical Analysis Plan Summary
Safety: Adverse experiences and discontinuation of study intervention due to adverse events 
will be tabulated. Separately for each panel , summary statistics and plots will be generated 
for raw laboratory safety tests, 12 -lead ECGs, and/or VS as well as for change from baseline, 
as deemed clinically appropriate. Depending on the safety parameter, the difference from 
baseline will either be computed on the original scale (raw change from baseline) or on the 
log scale and back transformed forreporting (percent change from baseline). Day -[ADDRESS_952687] -dose 12- lead ECG and vital sign 
readings.
Summary statistics and plots will be generated for BP RS,BARS, AIMS, SAS, as well as for 
change from baseline. The difference from baseline will be computed on the original scale 
(raw change from baseline). Responses to the C -SSRS will be listed. The Columbia Suicide 
Severity Rating Scale (C -SSRS) will be us ed to systematically and prospectively ascertain 
and document the occurrence of suicidal events (i.e., ideation and behavior).
9.[ADDRESS_952688] auspi[INVESTIGATOR_26338], the Early Clinical Development Statistics Department in collaboration
with the Quantitative Pharmacology and Pharmacometrics Department and Translational
Medicine Department of the Sponsor. If, after the study has begun, changes are mad e tothe 
statistical analysis plan stated below, then these deviations to the plan will be listed, along
with an explanation as to why they occurred, in the Clinical Study Report.
9.3 Hypotheses/Estimatio n
The objectives are listed in section 3.[ADDRESS_952689]:   MK-8189  87
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
9.4 Analysis E ndpoints
Primary Endp oints
Safety endpoints will include adverse experiences and discontinuation of study intervention 
due to adverse events .
Exploratory Endpoints
Safety: Laboratory safety tests, 12 -lead ECGs, and VS. Baseline is defined as Day - 1 or Day 
-2readings for laboratory safety tests. Day -1 9-hour reading will serve as time-matched 
baseline for the corresponding postdose 12-lead ECG and vital sign readings.
BPRS ,BARS, AIMS, SAS for all participants. The Columbia Suicide Severity Rating Scale 
(C-SSRS) will be used to systematically and prospectively ascertain and document the 
occurrence of suicidal events (i.e., ideation and behavior). 
PK variables: AUC0 -24, Cmax ,C24, AUC0 -inf, Tmax, CL/F, Vz/F, and apparent t1/2 .
Cardiodynamics (Panel C only) : QTc change from baseline (Holter ECGs ), HR, RR interval, 
PR interval, and QRS duration. U and T wave morphology.
9.5 Analysis Populations
The following populations are defined for th e analysis and reporting of data.  All participants
will be reported, and their data analyzed, according to the treatment(s) they actually received. 
All Participants as Treated (APasT): The All Participants as Treated Population consists of 
allparticipants who received at least one dose of treatment .  This population will be used for 
assessments of safety and tolerability.
Per-Protocol (PP) : The Per -Protocol Population consists of t he set of data generated by [CONTACT_701729] y with the protocol sufficiently to ensure that these data will 
be likely to exhibit the effects of treatment, according to the underlying scientific model. 
Compliance covers such considerations as exposure to treatment, availability of 
measurements and a bsence of major protocol deviations .  Major protocol deviations will be 
identified to the extent possible prior to unblinding by [CONTACT_100935]/compliance, and its analysis and interpretation.  Any participants or data values 
excluded from analysis will be identified, along with their reason for exclusion, in the CSR.  
At the end of the study, all participants who are compliant with the study procedure as 
aforementioned and have available data from at least one treatment (dose l evel) will be 
included in the Per -Protocol dataset. This population will be used for the PK and 
Concentration- QTc analyses.
08D4MT
PRODUCT:   MK-8189  88
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
9.6 Statistical Methods
Safety
Adverse experiences and discontinuation of study intervention due to adverse events will be 
tabulated. 
Separately for each panel, s ummary statistics and plots will be generated for raw laboratory 
safety tests, 12 -lead ECGs, and VS as well as for change from baseline, as dee med clinically 
appropriate. Depending on the safety parameter, the difference from baseline will either be 
computed on the original scale (raw change from baseline) or on the log scale and back
transformed for reporting (percent change from baseline). Day -[ADDRESS_952690] -dose ECG and vital sign readings.
Summary statistics and plots will be generated for BPRS , BARS, AIMS, SAS as well as for 
change from baseline. The difference from baseline will be computed on the original scale 
(raw change from baseline). Responses to the C -SSRS will be listed. The Columbia Suicide 
Severity Rating Scale (C -SSRS) will be used to syste matically and prospectively ascertain 
and document the occurrence of suicidal events (i.e., ideation and behavior). Responses on 
the C -SSRS are classified according to [ADDRESS_952691] categories (suicidal ideation, suicidal 
behavior, and non- suicidal self -injurious behavior) reported at a visit will be used for analysis 
and reporting. An event is considered treatment -emergent during the assessment phase if it is 
either newly eme rged or is more severe than the most severe event reported to have occurred 
in the trial -defined pre -treatment reference period. Individual C -SSRS listings will be 
provided.
Pharmacokinetics
Model -Based PK Summary
Separately f oreach panel and separately for each PK parameter, individual values of AUC0 -
24, Cmax, and C24 at each dose level will be natural log- transformed and evaluated with a 
linear mixed effects model containing a fixed effect for dose , day (where applicable), and a 
random effect for subject. Kenward and Roger's method will be used to calculate the 
denominator degrees of freedom for the fixed effects. Ninety- five percent confidence 
intervals (CIs) for the least squares means for each dose will be constructed on the natural log 
scale and will reference the t- distribution. Exponentiating the least-squares means, and lower 
and upper limits of these CIs will yield estimates for the population GMs and 95% CIs about 
the GMs on the original scale .
08D4MT
PRODUCT:   MK-8189  89
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Descriptive Statistics 
For each panel i ndividual values will be listed for each PK parameter by [CONTACT_701730] (where 
applicable) , and the following (non -model -based) descriptive statistics will be provided: N 
(number of participants with non- missing data), arithmetic mean, standard deviation, 
arithmetic  percent CV (calculated as [ADDRESS_952692] deviation/arithmetic mean), median, 
minimum, maximum, GM, and geometric percent CV (calculated as  100 x sq rt(exp(s2) -1), 
where s2is the observed variance on the natural log -scale).
Cardiodynamics :
The exploratory objective pertaining to QTc will be evaluated through development of a 
model describing the relationship between MK- 8189 plasma concentrations and QTc change 
from baseline in participants with schizophrenia (Panel C).Details of the concentration -QTc 
analysis will be specified in a separate modeling analysis plan (MAP). This MAP will be 
completed prior to unblinding and database lock. Results of this analysis will be reported 
separ ately from the CSR.
9.7 Interim Analyses
No interim analysis is planned.
9.8 Multiplicity
No multiplicity adjustments are needed, as there are no hypotheses.
9.9 Sample Size and Power Calculations
Since there are no hypotheses, no power calculations are provided. For evaluation of the 
relationship between QTc and plasma concentrations, the number of dose levels being 
evaluated and the number of participants on each treatment is consistent with those deemed 
to be adequate in the white paper [Mehrotra, D. V., et al 2017] .
08D4MT
PRODUCT:   MK-8189  90
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_952693], NJ, [LOCATION_003] (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall b e endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trial s that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator- initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_701719], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or valid ate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . All trial protocols are and will be assessed for the need and capability to enroll 
underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD ’s clinical trials are conducted globally in many different countries and in diverse populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of facilities 
and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial i nitiation, 
sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability to 
successfully conduct the trial.
Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts 
to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage 
08D4MT
PRODUCT:   MK-8189  91
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
underrepresented groups and those disproportionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately 
use the products under investigation.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incide nts/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothes is testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations publishe d by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independ ent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protoc ol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes t o the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant saf ety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Partic ipants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greate st extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
08D4MT
PRODUCT:   MK-8189  92
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications result ing from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Finan cial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor ’s responsibility to determine, based on these regulations, whether a request fo r 
financial d isclosure information is required. It is the investigator ’s/subinvestigator ’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certificati on/Disclosure Form, frequent ly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
08D4MT
PRODUCT:   MK-8189  93
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952694] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifie r by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be i nformed that his/her personal study- related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator af firms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_677719], except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponso r representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be identified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
08D4MT
PRODUCT:   MK-8189  94
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952695] 
proprietary inform ation and to provide comments.
Authorship will be determi ned by [CONTACT_11403] I CMJE authorship 
requirement s.
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is so lely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trials directive mandated trials . 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_88712] -site contact [CONTACT_3031].
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally manda ted registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to those 
registries.
10.1.[ADDRESS_952696] the study in an effi cient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, I CH GCP: Consolidated Guideline and other generally accepted standards of GCP ); and 
all applicable federal, state and local laws, rules and regulation s relating to the conduct of the 
clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduc t for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
08D4MT
PRODUCT:   MK-8189  95
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on cli nical studies by [CONTACT_19500]’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or i f any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened .
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or desi gnee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management proced ures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_123679], 
copying, review, and audit at reasonable times by [CONTACT_19502]. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a resul t of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being c onducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent , pertaining to 
the conduct of this s tudy must be retained by [CONTACT_1732] [ADDRESS_952697]:   MK-8189  96
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.[ADDRESS_952698] udy or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08D4MT
PRODUCT:   MK-8189  97
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 7will be performed by [CONTACT_12082].
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by t he investigator or required by [CONTACT_1295], to establish the absence 
of pregnancy at any time during the subject's participation in the study.
Table 7 Protocol -required Safety Laboratory Assessments
Laboratory 
Assessments Paramet ers
Hematology Platelet Count RBC Indices:
MCV
MCH
ReticulocytesWBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Chemistry BUN Potassium AST/SGOT Total bilirubin (and 
direct bilirubin, if 
total bilirubin is 
above the ULN)
Albumin Bicarbonate or CO2 Chloride Phosphorous
Creatinine Sodium ALT/SGPT Total Protein
Glucose [ fasting] Calcium Alkaline 
phosphataseMagnesium
Routine Urinalysis•Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
Pregnancy Testing•Highly sensitive serum or urine hCG pregnancy test (as needed for WOCBP)
Other Screening 
Tests•FSH (as needed in WONCBP only)
• A lcohol and drug screen (to include at minimum: amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651]) if applicable]
•Serology [(HIV antibody, HBsAg, and hepatitis C virus antibo dy
08D4MT
PRODUCT:   MK-8189  98
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Laboratory 
Assessments Paramet ers
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle -
stimulating hormone; [HBsAg=hepatitis B surface antigen]; hCG=human chorionic gonadotropin; 
[HIV=human immunodeficiency virus]; MCH=mean corpuscular hem oglobin; MCV=mean corpuscular 
volume; RBC=red blood cell; SGOT=serum glutamic -oxaloacetic transaminase; SGPT=serum glutamic -
pyruvic transaminase; ULN=upper limit of normal; WBC=white blood cell; WOCBP=women of 
childbearing potential; WONCBP=women of nonchi ldbearing potential
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
Laboratory/analyte results that could unblind the study will not be reported to investigative 
sites or other blinded personnel until the study has been unblinded.
08D4MT
PRODUCT:   MK-8189  99
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_952699].
10.3.2 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutic al product, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run- in 
intervention) , manufactured by, lic ensed by, provided by, or distributed by [CONTACT_701731].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
08D4MT
PRODUCT:   MK-8189  100
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
•Exacerbation of a chronic or intermittent preexisting condition includin g either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
Event s NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307] ).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexisting condition 
that has not worsene d.
•Refe r to Section 8.4.[ADDRESS_952700] medical occurrence that, at any dose :
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
08D4MT
PRODUCT:   MK-8189  101
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condition that has not 
worsened is not an SAE. )A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or sig nificant disability/incapacity
•The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of part icipant taking the product regardless of time to diagnosis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
notbe immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] 1 
of the other outcomes listed in the above definition. These events should usually be 
considered serious.
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug depe ndency 
or drug abuse.
10.3.4 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
08D4MT
PRODUCT:   MK-8189  102
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.3.5 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assess ment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following
categories:
-Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal 
discomfort, and not interfering with everyday activities (for pediatric studies, 
awareness of symptoms, but easily tolerated).
-Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wro ng).
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with an SAE. Severe is a category used for rating the intensity of an 
event; and both AE and SAE can be assessed as severe (for pediatri c studies, extremely 
distressed or unable to do usual activities).
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
08D4MT
PRODUCT:   MK-8189  103
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified asse ssment of causality was done . This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor ’s product such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc), exp ected pharmacologic effect, or measurement of 
drug/metabolite in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? Is the time of onset of the AE compatible 
with a drug -induced e ffect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Spons or’s product discontinued or dose/exposure/frequency 
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despi[INVESTIGATOR_55530] ’s 
product; (3) the study is a single -dose drug study; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this 
study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
08D4MT
PRODUCT:   MK-8189  104
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POS ES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC .
•Consistency with study intervention profile: Is the clinical/pathological presentat ion of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the CRFs /worksheets by [CONTACT_26368] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility of S ponsor’s product relationship:
◦There is evidence of exposure to the Sponsor ’s product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ’s product is 
reasonable. The AE is more likely explained by [CONTACT_1034] ’s product than by 
[CONTACT_5748].
-No, there is not a re asonable possibility of Sponsor’ s product relationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not re asonable 
OR the AE is more likely explained by [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•The investigator must review and provide an assessment of causality for each AE/SAE 
and docume nt this in the medical notes .
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242] -up information 
and send an SAE follow- up report with the updated causality assessment.
08D4MT
PRODUCT:   MK-8189  105
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Thecausality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care profess ionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.6 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or recei ves updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
08D4MT
PRODUCT:   MK-8189  106
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08D4MT
PRODUCT:   MK-8189  107
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
Not applicable.
08D4MT
PRODUCT:   MK-8189  108
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of st udy intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.
Note : Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_952701]:   MK-8189  109
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc,d
•IUSc,e
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner 
of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User De pendentb
Failure rate of <1% per year when used consistently and correctly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study intervention. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of 
action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical c ap, diaphragm, or sponge with spermicide (double 
barrier methods) .
aContraceptive use by [CONTACT_93339].
bTypi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and 
correctly).
cMale condoms must be used in addition to female participant hormonal contraception.
dIf locally required, in accordance with CTFG guidelines, acceptable hormonal cont raceptives are limited 
to those which inhibit ovulation.
eIUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and LAM.
-Male and female condom should not be used together (due to risk of failure with friction ).
08D4MT
PRODUCT:   MK-8189  110
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions
a.Biomarker: A biological molecule found in blood, other body fluids, or tissues that 
isa sign of a normal or abnormal process or of a condition or disease. A biomarker 
may be used to see how well the body responds to a treatment for a disease or 
condition .1
b.Pharmacogenomics: The investigation of variations of DNA and RNA 
characteristics as related to drug/vaccine response.2
c.Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the 
influence of variations in DNA sequence on drug/vaccine response.2
d.DNA: Deoxyribonucleic acid.
e.RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research3, 4
The specimens consented and/or collected in this study as outlined in Section 8. 9will 
be used in various experiments to understand:
    The biology of how drugs/vaccines work
    Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
    Other pathways with which drugs/vaccines may interact
    The biology of disease
The specimen(s) may be used for future assay deve lopment and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our und erstanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_75402].
08D4MT
PRODUCT:   MK-8189  111
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
3. Summary of Pro cedures for Future Biomedical Researc h3, 4
a.Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in 
future biomedical research.
b.Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be presented to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRF s. Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional b lood specimens ar e being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4. Confidential Participant Information for Future Biomedical Research3, 4
In order t o optimize the resea rch that can be conducted with future biomedical research
specimens, it is critical to link participant s' clinical information with future test results. 
In fact ,little or no research can be conducted without connecting the clinical study data 
to the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
08D4MT
PRODUCT:   MK-8189  112
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers 
will appear on the specimen tube.
5. Biorepository Specimen Usage3, [ADDRESS_952702] party (eg, a university investigator) designated by 
[CONTACT_1034]. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to 
the specific scope o f analysis outlined in future biomedical research protocol and 
consent . Future biomedical research specimens remaini ng with the third party after 
specific analysis is performed will be reported to the Sponsor.
6. Withdrawal From Future Biomedical Research3, [ADDRESS_952703] the Sponsor using the designated mailbox 
(clinical.specimen.management@ MSD .com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be 
removed from the biorepository and destroyed. Documentation will be sent to the 
investigator confirming withdrawal and/or destruction, if applicable. It is the 
responsibility of the investigator to inform the participant of completion of the 
withdrawal and/or destruction, if applicable. Any analyses in progress at the time of 
request for withdrawal/destruction or already performed before the request being 
received by [CONTACT_701732]. No new analyses would be generated after the request is recei ved.
If the medical records for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
partici pant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens3, [ADDRESS_952704]:   MK-8189  113
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952705] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants3, 4
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: lack of relev ance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_88726].
10. Future Biomedical R esearch Study Population3, [ADDRESS_952706] security, policies, and procedures to address 
participant data privacy concerns. Data privacy risks are lar gely limited to rare 
situations involving possible breach of confidentiality. In this highly unlikely situation, 
there is risk that the information, like all medical information, may be misused.
12. Questions
Any questions related to the future biomedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
08D4MT
PRODUCT:   MK-8189  114
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
13. References
1.National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/effi cacy-single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biom arker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4.Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.org/
08D4MT
PRODUCT:   MK-8189  115
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.7 Appendix 7: Country -specific Requirements
Not applicable.
08D4MT
PRODUCT:   MK-8189  116
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.8 Appendix 8:Blood Volume Table
Panels A, A-1, and C PrestudyTreatment 
Periods PoststudyTotal 
CollectionsmL Per 
Collection Total mL/ Test
Laboratory Safety Tests
includ ing serum β-hCG
(WOCBP) or serum FSH
(WONCBP) and BDS3 2 1 6 12 72
HIV/Hepatitis Screen (at the 
discretion of the investigator)1 1 4.5 4.5
Blood for Planned Genetic 
Analysis 1 1 8.5 8.5
Blood for MK-8189 Panel A 19 19 4 76
Blood for MK -8189 Panel A-1 19 19 4 76
Blood for MK -8189 Panel C 34 34 4 136
Total Blood Volume per Participant for Panel Aa161mL
Total Blood Volume per Participant for Panel A-1a161mL
Total Blood Volume per Participant for Panel Ca221 mL
aIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood ( no more than 
50mLin total ) may be obtained.
08D4MT
PRODUCT:   MK-8189  117
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
If criteria diverges from inclusion/exclusion criteria, more conservative criteria should 
be used.
Screen Failure CriteriaPotentially Significant 
Postrandomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm and HR increase of 
≥25bpm from baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of 
≥5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature Complex 1 beat 3 beats
Ventricular Premature Complex All 3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR 
<40bpmJunctional Rhythm with HR <[ADDRESS_952707] Degree AV Block PR 230 msPR 230 ms + Increase of 15 ms; 
or PR Increase of >25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree AV Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined AboveNew Onset RBBB (Not Including 
Rate-related)
ICRBBB (QRS <120 ms) No Exclusion Nothing
Short PR/Preexcitation Syndrome Delta Wave + PR <[ADDRESS_952708] + PR <120 ms
Other Intra -Ventricular Conduction 
DelayQRS 130 ms QRS 130 ms + Increase of 10 ms
QTc (B or F)
Male QTc 470 msQTc 500 ms or Increase of 60 ms 
From Baseline
Female QTc 480 msQTc 500 ms or Increase of [ADDRESS_952709]:   MK-8189  118
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Screen Failure CriteriaPotentially Significant 
Postrandomization Findings 
(clarification on action to take)
MYOCARDIAL INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST Elevation Suggestive of 
Myocardial Injury In [ADDRESS_952710] -T Changes 
(In 2 or More Leads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
AV=atrioventricular; bpm=beats per minute; HR=heart rate: ICRBBB=incomplete right bundle branch 
block; LAHB=left anterior hemiblock; LPHB=left posterior hemiblock; LVH=left ventricular hypertrophy; 
mm=millimeter; ms=milliseconds, PR=pulse rate; QTcB=QT cor rection using Bazett’s formula; QTcF=QT 
correction using Fredericia formula; RBBB=right bundle branch block; ST/T=ST- segment/T wave.
Baseline is defined as Predose Day [ADDRESS_952711]:   MK-8189  119
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory values obtained at prestudy (screening) visit and/or predose evaluation:
A.If all protocol- specified laboratory values are normal, the participant may enter the study.
B.If a protocol specified laboratory value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study.
C.If ≥1 protocol -specified laboratory value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
a.The participant may be excluded from the study;
b.The participant may be included in the study if the abnormal value(s) is NCS (the 
investigator must annotate the laboratory value “NCS” on the laboratory safety 
test source document).
c.The participant may be included in the study if the abnormality is consistent with 
a pre -existing medical condition which is not excluded per protocol (eg, elevated 
eosinophil count in a participant with asthma or seasonal allergies), the medical 
condition should be annotated on the laboratory report .
OR
d.The abnormal test may be repeated (refer items a. and b. below for continuation of 
algorithm for repeated values).
a.If the repeat test value is within the normal range, the participant may 
enter the study.
b.If the repeat test value is still abnormal, the study investigator will 
evaluate the potential participant with a complete history and physical 
examination, looking especially for diseases that could result in the 
abnormal laboratory value in question. If such diseases can be ruled out, 
and if the abnormal laboratory value is not clinically relevant, then the 
participant may enter the study.
D.If there is any clinical uncertainty regarding the significance of an abnormal value, the 
participant will be excluded from the study.
08D4MT
PRODUCT:   MK-8189  120
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.11 Appendix 11: Neurological Exam
The following assessments are provided as a nexample of what will be collected at the 
appropriate time points in the SoA, Section 1.3.  
The general (full) neurological exam and targeted neurological exam may be used for 
patient/subject assessment.  
10.11.1 General (Full) Neurological Exam
See SoA, Section 1.3 for specific timepoints.
The General Neurological Examination includes all of the modules listed below and is 
intended to be a general screening examination.
MODULE 1 – MENTAL STATUS EXAMINATION
A.General Level of Arousal: Generally assess general level of alertness, attentiveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired attention or concentration. For example, difficulty remembering or following 
instructions or distractibility may be signs of inattention.
B.Thought Processes and Language: Generally assess logic, rel evance, organization and 
coherence of volunteer’s use of language throughout the interview.
C.Orientation (time, place, person)
D.Attention/Concentration
Ask the subject to count backwards from 100 by 7’s (“Serial 7’s”) or ask to recite months 
backwards or spe ll a [ADDRESS_952712] ( eg,“WORLD”) backwards.  
Note : to avoid learning effects, switch between tests throughout the study
E.Memory:   Test registration of 3 objects; then test immediate recall 5 minutes later.
Grade : NORMAL or IMPAIRED and describe abnormality (for each, A to E, 
above).  Normal performance on Serial 7’s is getting to [ADDRESS_952713]:   MK-8189  121
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
MODULE 2 – CRANIAL NERVE ASSESSMENT
A. II–Visual Fields and acuity
B. II, III–Pupil Size and Reactivity
C. III, IV, VI–Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus)
1.Observe for nystagmus during eye movements, increased nystagmus at the end of 
gaze or other oculomotor changes (mild nystagmus at ext remes of gaze is normal). 
Note direction of nystagmus
D. V –Facial Sensation, Jaw Strength
E. VII–Muscles of Facial Expression (wrinkle brow, squeeze eyes shut, smile)
F. VIII –Auditory Acuity (assessed using a bed -side screening test e.g. by [CONTACT_98413] f ingers 
on each side of subject’s head or by [CONTACT_100939])
G. IX– Gag reflex
H. X –Swallow 
I. XI–Shoulder shrug
J. Tongue Protrusion (midline)
Score : left and right (except for G, H, J)
Grade : NORMAL or IMPAIRED and describe abnormality
MODULE 3 - MOTOR SYSTEM
A.Muscle Tone
1. Ask the volunteer to relax.
2.Flex and extend the volunteer’s elbows and at the knees (bilaterally). 
3.There is a small, continuous resistance to passive movement.
4.Observe for involuntary movements (e.g., tremor, tics, fasciculations). Observe for 
resistance to passive movement; observe for decreased (flaccid) or increased 
(rigid/spastic) tone.
Score :  left and right
Grade : NORMAL, INCREASED or DECREASED
08D4MT
PRODUCT:   MK-8189  122
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952714] to stand up from sitting without using hands
Grade: NORMAL, IMPAIRED and describe abnormality
2.Test proximal limb strength by [CONTACT_100940].
Test bilaterally, and compare one side to the other.
Score :  left and right
Grade : 5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
3.Test distal limb strength by [CONTACT_100941]’s feet; finger abduction and handgrip strength against your 
resistance.
Test bilaterally, and compare one side to the ot her.
Score :  left and right
Grade : 5/5: normal; 
4/5: movement against resistance impaired; 
3/5: movement against gravity but not against resistance; 
2/5: visible movement but not against gravity; 
1/5: visible contraction; 
0/5: no visible activity
C.Pronator Drift
1.Ask the volunteer to hold both arms straight forward with, palms up and eyes closed for 
~10-15 seconds as tolerated; watch for how well the arm position is maintained .
08D4MT
PRODUCT:   MK-8189  123
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952715]. The 
volunteer should normally be able to maintain extension and supi[INVESTIGATOR_20810]. Inability to 
maintain extension and supi[INVESTIGATOR_20810] (and drift into pronation) indicates an upper motor 
neuron deficit.
Score :  left and right
Grade : NORMAL or IMPAIRED and describe abnormality
MODULE 4 - REFLEXES
A.Biceps
B.Knee
Note :Other deep tendon reflexes may be tested at Investigator's discretion (e.g. elbow, 
wrist or Achilles tendon)
Score : left and right
Grade : NORMAL, INCREASED, DECREASED or ABSENT
C.Babinski
Score : left and right
Grade : NORMAL or ABNORMAL
MODULE [ADDRESS_952716] as possible. 
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject will be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
08D4MT
PRODUCT:   MK-8189  124
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
B.Point- to-Point Movements
1.Ask the volunteer to touch your index finger and their nose alternately several times.  
Move your finger about as the volunteer performs this task.
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the point -to-point testing is disturbed, the subject will be asked to place 
one heel on the opposite knee and then run it down the shin to the big toe.  Repeat this 
for both sides.  (Impaired tests indicate cerebellar disease.)
C.Romberg
1.Ask the volunteer to stand with both feet to gether and eyes closed for 20 to 
30seconds without support.
2.Be prepared to catch the volunteer if they are unstable.
Grade : NORMAL or IMPAIRED
D.Gait
1.Ask the volunteer to walk across the room, turn and come back (assess posture, 
balance, swinging o f arms and movement of the legs).
Grade : NORMAL or IMPAIRED and describe abnormality
2.Ask the volunteer to walk heel -to-toe in a straight line (tandem gait).
Grade : NORMAL or IMPAIRED and describe abnormality
08D4MT
PRODUCT:   MK-8189  125
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
MODULE 6 - SENSORY
A.Light touch sense :  cotton wisp on skin of forearms and legs, bilaterally.
B.Pin prick: safety pin touched lightly to skin of forearms and legs, bilaterally.
C.Temperature : warm or cool object touched to skin of forearms and legs, bilaterally.
D.Vibration:  tuning fork vibration detection in hands, feet bilaterally.
E.Position sense :  perception of thumb and toe movement, bilaterally.
F.Stereognosis :  (identify common objects placed in hand, e.g., coin, key).
Score : left and right
Grade : NORMAL OR IMPAIRED and describe abnormality (for each A to F)
10.11.2 Targeted Neurological Exam
See SoA, Section 1.3 for specific timepoints.
The Targeted Neurological Examination , which is intended to focus on tests where drug 
effects can be seen, includes the following tests only:
MODULE 1 – MENTAL STATUS EXAMINATION
A.General Level of Arousal :Generally assess general level of alertness, attentiveness, and 
concentration throughout the interview. Regarding attentiveness, note evidence of 
impaired at tention or concentration. For example difficulty remembering or following  
instructions or distractibility may be signs of inattention)
MODULE 2 – CRANIAL NERVE ASSESSMENT
B.II, III – Pupil Size and Reactivity
C.III, IV, VI – Extraocular Movements (range of motion, smooth pursuit, saccades, 
nystagmus)
1.Observe for nystagmus during eye movements, increased nystagmus at the end of 
gaze or other oculomotor changes (mild nystagmus at extremes of gaze is normal). 
Note direction of nystagmus
08D4MT
PRODUCT:   MK-8189  126
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
MODULE 3 - MOTOR SYSTEM
B.Muscle Tone
1. Ask the volunteer to relax.
2.Flex and extend the volunteer’s elbows (may also move wrists simultaneously) and at 
the knees (bilaterally). When testing the upper limbs, do this again while the subject 
makes large repetitive movements with the opposite arm (e.g. patting the palm of the 
hand on the knee). 
3.There is a small, continuous resistance to passive movement.
Score :  left and right
Grade: NORMAL, IMPAIRED, or DECREASED and describe abnormality
MODULE [ADDRESS_952717] as possible. 
Score : left and right
Grade : NORMAL or IMPAIRED
Reminder : If the rapid alternate movements are disturbed, the subject wi ll be asked to 
strike his hand on the thigh, raise the hand, turn it over and then strike the back of the 
hand down on the same place.  (This test is impaired in cerebellar disease, extra 
pyramidal disease and upper MN weakness.)
D.Gait
2.Ask the volunte er to walk heel -to-toe in a straight line (tandem gait).
Grade : NORMAL or IMPAIRED and describe abnormality
MODULE 6 - SENSORY
A.Light touch sense:  cotton wisp on skin of forearms and legs, bilaterally.
08D4MT
PRODUCT:   MK-8189  127
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
10.12 Appendix 12: Abbreviations
Abbreviation Expanded Term
ACCP Americ an College of Chest Physicians
ADA anti drug antibodies
ADL activities of daily living  
ADME absorption, distribution, metabolism, and excretion
AE adverse event 
AIMS abnormal involuntary movement scale
ALP alkaline phosphatase
ALT alanine aminotransferase
APaT All-Participants -as-Treated
AR adverse reaction
ART anti retroviral therapy
AST aspartate aminotransferase
ATD accelerated titration design
ATP adenosine triphosphate
AUC area under the curve
BARS Barnes Akathisia Rating Scale
BCG Bacillus Calmette –Guérin
BDS blood drug screen
BICR blinded independent central review
bid twice daily
BMI body mass index
BP blood pressure
BPRS Brief Psychiatric Rating Scale
CAC Clinical Adjudication Committee
CCU Cardiac care unit
CD28 cluster of differentiation [ADDRESS_952718]:   MK-8189  128
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952719]:   MK-8189  129
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952720]
IA(s) interim analysis(ses)
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International C ouncil for Harmoni sation of Technical Requirements for 
Pharmaceuticals for Human Use
ICMJE International Committee of Medical Journal Editors
iCRO imaging CRO
ICU intensive care unit
IEC Independent Ethics Committee
Ig immunoglobulin
IgG4 immunoglobulin G4
IgV immunoglobulin -variable
IHC immunohistochemistry
IND Investigational New Drug 
IO immune -oncology
irAEs immune -related AEs
IRB Institutional Review Board
iRECIST Response Evaluation Criteria in Solid Tumors 1.[ADDRESS_952721]:   MK-8189  130
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
Abbreviation Expanded Term
MRI magnetic resonance imaging
mRNA messenger RNA
MSI microsatellite instability
MTD maximum tolerated dose 
mTPI [INVESTIGATOR_701720]–small cell lun g cancer
NDA New Drug Application 
NOAEL no observed adverse effect level 
OR objective response
ORR objective response rate
OS overall survival
OSF on-site formulation
OTC over-the-counter
PBPK physiologically -based PK
PCL Protocol Clarification Letter
PD-[ADDRESS_952722]:   MK-8189  131
PROTOCOL/AMENDMENT NO.:   [ADDRESS_952723](s)
SoA schedule of activities
SOC standard of care
SOP Standard Operating Procedures
sSAP supplemental Statistical Analysis Plan
STING stimulator of interferon genes
S[LOCATION_003]R suspected unexpected serious adverse reaction
SVR12 sustained viral response
TEA Treatment Eligibility Assessment (form)
Tmax Time to maximum plasma concentration
TMDD target-mediated drug disposition
t1/[ADDRESS_952724] infection
UTN Universal Trial Number
Vd volume of distribution
VS vital signs
WBC white blood cell
WPAI Work Productivity and Activity Impairment
WOCBP woman/women of childbearing potential
WONCBP woman/women of nonchildbearing potential
ZAP70 zeta-chain -associated protein kinase
08D4MT
PRODUCT:   MK-8189  132
PROTOCOL/AMENDMENT NO.:   014 -05  
MK-8189 -014-05FINAL PROTOCOL 18-NOV -2022
11 REFERENCES
[Bender, A. T. and Beavo, J. 
A. 2006]Bender AT, Beavo JA. Cyclic nucleotide 
phosphodiesterases: molecular regulation to 
clinical use. Pharmacol Rev 2006;58:488 -
520.[03RW09]
[European Medicines Agency 
2022]European Medicines Agency. ICH 
guideline E14/S7B: clinical and nonclinical 
evaluation of QT/QTc interval prolongation 
and proarrhythmic potential - questions and 
answers. Amsterdam (Netherlands): 
European Medicines Agency (EMA); 2022. 
37 p. EMA/CHMP/ICH/415588/2020.[085Y6Q]
[Grauer, S. M., et al 2009] Grauer SM, Pulito VL, Navarra RL, Kelly 
MP, Kel ley C, Graf R, et al. 
Phosphodiesterase 10A inhibitor activity in 
preclinical models of the positive, 
cognitive, and negative symptoms of 
schizophrenia. J Pharmacol Exp Ther 
2009;331(2):574 -90.[03RW0C]
[Mehrotra, D. V., et al 2017] Mehrotra DV, Fan L, Li u F, Tsai K. 
Enabling robust assessment of QTc 
prolongation in early phase clinical trials. 
Pharm Stat. 2017;16:218 -27.[04XCJJ]
[Schmidt, C. J., et al 2008] Schmidt CJ, Chapin DS, Cianfrogna J, 
Corman ML, Hajos M, Harms JF, et al. 
Preclinical characteriz ation of selective 
phosphodiesterase 10A inhibitors: a new 
therapeutic approach to the treatment of 
schizophrenia. J Pharmacol Exp Ther 
2008;325(2):681 -90.[03RW0F]
[Seeger, T. F., et al 2003] Seeger TF, Bartlett B, Coskran TM, Culp 
JS, James LC, Krull DL , et al. 
Immunohistochemical localization of 
PDE10A in the rat brain. Brain Res 
2003;985:113- 26.[03RW0G]
08D4MT